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Chapter I 
SCOPE OF THIS THESIS 
Mammary cancer has been a challenge to researchers for 
many years, because of the continuous menace of this disease 
to (wo)mankind. Since it is difficult to study the mechanism 
of mammary gland carcinogenesis experimentally in the human, 
model systems had to be devised. "Spontaneous" mammary 
tumours in rats are quite rare, or occur only after a very 
long period (Burek & Hollander, 1977; Burek, 1978). There-
fore, induction of tumours has been used to obtain large 
amounts of tumour tissue. Two tumour model systems which are 
relevant to the work presented in this thesis will be 
described in some detail. 
Induction of mammary tumours by oestrogens and/or ioni-
zing radiation was used for most of the experiments reported 
in this thesis. This tumour model has received much attention 
since it became clear, that ionizing radiation could cause 
mammary cancer in human females e.g. after the exposure to 
radiation from atomic bombings at the end of World War II 
(Wanebo et al., 1968; Land & McGregor, 1979) or after exposure 
to therapeutic and diagnostic doses of X-rays (Baral et al., 
1977; Boice & Monson, 1977; Shore et al·., 1977). There were 
several indications that in rodents treatment with oestrogens 
may initiate mammary gland carcinogenesis (Lacassagne, 1932; 
Meites, 1972; Noble et al., 1975; Rudali et al., 1975; Lemon, 
1977). It is thought, however, that oestrogens would act 
partly through an increase in pituitary prolactin release 
(M~hlbock & Boot, 1967) and partly synergistic with prolactin 
(Meites, 1972). Furthermore, in the rat a synergistic action 
of oestrogens and radiation has been observed (Segaloff & 
Maxfield, 1971; Shellabarger et al., 1976). This finding, to-
gether with the wide-spread use of oestrogen-containing oral 
contraceptives (Rinehart & Piotrow, 1979) and an increased 
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exposure to radiation (Upton, 1975), point to the possibility 
that part of the mammary tumours observed in women could also 
have arisen, or will arise as a result of a synergistic inter-
action between oestrogens and ionizing radiation. 
The aim of the studies presented in this thesis was to 
gain a better understanding of the contribution and mecha-
nism(s) of action of oestrogens and prolactin in the develop-
ment of mammary cancer. The presence of oestrogen receptors 
in human and rat mammary tumours and the correlation between 
the presence of receptors and the rate of success of endocrine 
therapy strongly suggest that the (co)carcinogenic action of 
oestrogens on the mammary gland is mediated by the oestrogen 
receptors. Since oestrogens are capable of inducing their own 
receptors (Sarff & Gorski, 1971; Mester & Baulieu, 1975; 
Baudendistel et al., 1978), the first event in oestrogen-
mediated mammary gland carcinogenesis could be an increase in 
the mammary gland oestrogen receptor content. To detect such 
a possible increase, oestrogen receptors were estimated in 
mammary glands during the process of carcinogenesis rather 
than in tumours which had developed after the administration 
of carcinogenic stimuli, as has been done in all experiments 
reported in the literature sofar. Since administration of 
oestrogens to rats is known to increase the release of pro-
lactin from the pituitary (Chen & Meites, 1970; Vander 
Gugten et al., 1970), plasma prolactin levels were estimated 
in an attempt to correlate effects on prolactin with other 
effects of oestrogen. 
The first part of this thesis deals with the induction 
of mammary tumours and the method used for the administration 
of oestrogen to rats to obtain slightly elevated plasma 
oestrogen levels. Subsequent sections concern the method used 
for the estimation of oestrogen receptors in tissues from 
oestrogen-treated animals and the results of the estimation 
of oestrogen receptors in mammary glands and plasma prolactin 
of rats exposed to amounts of oestrogen and radiation which 
were expected to induce mammary carcinogenesis. 
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Chapter 2 
INTRODUCTION 
For proper differentiation, development and functioning, 
the mammary gland is dependent on several hormones 
(R.R. Anderson, 1974). Insulin accelerates the growth of the 
primary sprouts and insulin and prolactin act synergistically 
to stimulate further growth and development. For differentia-
tion of the fetal gland into the ductal system, aldosterone 
is required in addition. Prolactin and progesterone are re-
quired for further growth and secretory activity (Ceriani, 
1970). The allometric growth of the mammary tissue, which 
occurs before puberty, is thought to be caused by cyclic pro-
duction of oestrogens by the ovary (Sinha & Tucker, 1969). 
During pregnancy, a further growth of the mammary tissue is 
observed, which requires prolactin, growth hormone, adrenal 
corticoids and thyroid hormone (R.R. Anderson, 1974). Finally, 
for lactation the presence of oxytocin, prolactin, growth 
hormone, thyroxine, adrenal corticoids and parathyroid hor-
mone is necessary (Turner, 1974). For maintenance of mammary 
epithelial cells in culture, insulin and corticoids are re-
quired (Welsh et al., 1976; Hallowes et al., 1977). 
2.2. ~ff~~£~-~f-~~E~~TI~~-£g_~~~~~El_gl~TI~-S~E£ig~g~g~~i~_ig 
the rat 
-------
Mammary cancer in laboratory rats can develop "spontane-
ously'' or after exposure of the animals to chemical or physi-
cal carcinogenic stimuli. Among the factors known to contri-
bute to neoplastic transformation of the mammary gland are 
ionizing radiation (Segaloff & Maxfield, 1971; Shellabarger 
et al., 1976 and Broerse et al., 1978) and chemical carcino-
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gens like dimethyl-benzanthracene (DMBA) (Huggins et al., 
1959), N-nitrosobutylurea (Takizawa, 1973) and N-nitrosome-
thylurea (Chan et al., 1977). The response to carcinogenic 
agents is strongly dependent on the nutritional and endocrine 
status of the animals. A high dietary fat intake promotes the 
induction of mammary tumours by N-nitrosomethylurea (Chan et 
al., 1977) and DMBA (Hill et al., 1977), whereas ovariectomy 
greatly reduces the carcinogenic action of DMBA (Dao, 1962) 
and ionizing radiation (Broerse et al., 1978). Ovarian hor-
mones apparently play a permissive role in rat mammary gland 
carcinogenesis. On the other hand it has been shown, that 
oestrogens may act synergistically with ionizing radiation in 
the induction of mammary cancer in the rat (Segaloff & 
Maxfield, 1971; Shellabarger et al., 1976 and Broerse et al., 
1978). The mechanism through which oestrogens exert this 
synergistic action is still unknown. 
Also for prolactin a cocarcinogenic action in rat mam-
mary gland carcinogenesis has been demonstrated (Van der 
Gugten et al., 1973). 
The presence of oestrogen receptors in human mammary tu-
mours has been studied extensively. Approximately 60% of pri-
mary mammary tumours in women contain detectable amounts of 
oestrogen receptors (McGuire et al., 1975; Koenders, 1979). 
The significance of the presence of oestrogen receptors in 
mammary tumours as a means of predicting the response of the 
tumour to ''endocrine therapy'', has been strongly emphasized. 
In a collaborative study of eight cancer institutes 54% of 
''oestrogen receptor positive'' mammary tumours regressed after 
endocrine therapy, whereas only 5% of ''oestrogen receptor 
negative'' tumours showed a regression (McGuire et al., 1975). 
Also in DMBA-induced rat mammary tumours oestrogen re-
ceptors have been demonstrated (e.g. Nicholson et al., 1976: 
Vignon & Roch-:fort, 1976; Tsai & Katzenellenbogen, 1977). 
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These tumours also regress after ovariectomy {Mobbs & Johnson, 
1974; Fiebig & Schmahl, 1977). The correlation between the 
presence of oestrogen receptors and the result of endocrine 
therapy is beyond doubt, but the mechanism(s) through which 
the different endocrine therapies which have been used 
cause(s) the therapeutic effect, is ill understood, as is the 
role which oestrogen receptors could play in carcinogenesis. 
It is generally accepted that oestrogens act on their 
target tissues through specific receptor molecules present 
in the target cells. Several recent reviews on this topic are 
available (e.g. King & Mainwaring, 1974; Chan & O'Malley, 
1976; Van Beurden, 1977; De Boer, 1977; O'Malley & Birnbaumer, 
1978), but within the context of this thesis it appears appro-
priate to discuss briefly some general aspects of the mecha-
nism of oestrogen action in general and the possible role of 
oestrogen receptors in the action of oestrogens on the mammary 
gland and in mammary carcinogenesis. Most of the work done to 
elucidate the mechanism of action of oestrogens has been per-
formed on chicken liver and oviduct and on calf and rat ute-
tus, but for the present discussion the information available 
is considered to be valid for other oestrogen target tissues 
as well. 
In the circulation, oestradiol is present mainly bound 
to plasma proteins, which have a large binding capacity, a 
-6 
moderate to high binding affinity (Kd = 10 ~),but a low 
binding specificity (Westphal, 1971). In human plasma sex 
hormone binding globulin (SHBG) is present which binds testo-
sterone and oestradiol with high affinity, but low capacity 
(Murphy, 1968; D.C. Anderson, 1974). A comparable high affi-
nity binder for oestradiol has not been observed in adult rat 
plasma (Murphy, 1968). In young rats, however, a high affinity 
oestradiol binding protein, a-fetoprotein, is present (Nunez 
et al., 1971). Such a protein has also been found in mammary 
19 
tumours (Nakao et al., 1978). 
The free oestradiol present in the plasma can pass the 
cell membrane by simple diffusion (MUller et al., 1979). In 
the plasma of target cells the oestradiol encounters proteins 
which have a limited number of high-affinity, oestrogen-
specific binding sites. These proteins are termed ''Receptors''. 
In this regard, a-fetoprotein is not identical to the oestra-
diol receptor (Radanyi et al., 1977). After binding of oestra-
diol to its cytoplasmic receptor the oestradiol-receptor com-
plex undergoes a heat- and temperature-dependent conformational 
change which activates the complex to translocate to the nu-
cleus (Gorski et al., 1968; Jensen et al., 1968; DeSombre et 
al., 1975; Weichman & Notides, 1977). The nucleus is thought 
to contain at least two types of binding sites for the oestra-
diol-receptor complex. In the model proposed by Yamamoto & 
Alberts (1975) it is suggested that the oestradiol-receptor 
complex exerts its effects by binding to a limited number of 
high affinity acceptor sites on the chromatin. In addition, 
the oestradiol-receptor complex would have a low affinity for 
non-specific DNA sequences, which would outnumber the specific 
binding sites. Translocation of oestrogen receptors to the 
nuclei will result in an increase of mRNA synthesis (Means et 
al., 1975; Schimke et al., 1975; Woo & O'Malley, 1975). 
Palmiter et al. (1976) have suggested that oestrogen-receptor 
complexes which bind to the high affinity DNA binding sites 
move along the genome, in a manner comparable to ribosome 
translocation along mRNA, until they encounter a locus where 
they can influence mRNA production. In contrast, oestrogen-
receptor complexes which bind to the non-specific DNA sequen-
ces are not capable of such a translocation and exert no 
effect on the cell. The mRNA formed as a result of the inter-
action of the oestrogen-receptor complex with the genome is 
translated on the ribosomes and new proteins are synthesized 
which may cause a change in the metabolic activity of the 
cell. Among the effects oestrogens have on target tissues are 
the increased syntheses of the so-called ''Induced Protein'' 
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Figure 2.1. Simplified scheme for the action of oestrogens 
(E) on their target cells. 
Free oestrogens (E) enter the cell, bind to the cytoplasmic 
oestrogen receptor (Rc) to form the oestrogen-receptor com-
plex (ERe). This ERe migrates into the nucleus (ERn). Binding 
of ERn to the chromatin triggers RNA synthesis which ultima-
tely results in the hormonal effect. Receptors in the cytosol 
could be replenished by synthesis (S) and/or reactivation (R) 
as discussed in section 2.4. 
(I.P.) (Notides & Gorski, 1966; Means et al., 1975; Schimke 
et al., 1975), of ovalbumin (Palmiter et al., 1976) and of 
several nuclear proteins (Hemminki, !977). 
After completing its task, the oestradiol-receptor com-
plex has to dissociate from its nuclear binding site. It is 
still unclear whether the receptor is degraded or partly re-
used for binding of oestradiol. A simplified scheme of oestro-
gen action on its target cell is given in Figure 2.1. 
The results of several recent investigations have raised 
some questions concerning the general validity of the 
described model of oestrogen action depicted above. The demon-
stration of unoccupied_nuclear oestrogen receptors in human 
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mammary tumours (Garola & McGuire, 1977; Zava et al., 1977) 
and pig uterus (Jungblut et al., 1978) makes an obligatory 
role of oestradiol on receptor activation and translocation 
questionable. In addition, Linkie & Siiteri (1978) have sug-
gested that the translocation of the steroid-receptor complex 
would be a process of simple diffusion and that the transfor-
mation of receptors would occur in the nucleus. A third com-
plicating factor is the presumed presence of more than one 
oestradiol receptor in target tissues (Clark et al., 1978; 
Eriksson et al., 1978). In spite of these apparently contra-
dictory findings, there is ample information that justifies 
for the time being to accept the scheme depicted in Figure 
2.1 as a working hypothesis for the biochemic2l mechanisms 
involved in hormone action. 
Based on the model of hormone action presented in Figure 
2.1, the effect of a hormonal stimulus is believed to depend 
on the number of hormone-receptor complexes which are bound 
to the target cell chromatin, hence a response would directly 
depend on the number of receptor sites available for hormone 
binding. From data obtained by Sarff & Gorski (1971) and 
Mester & Baulieu (1975) it appears that the number of receptor 
sites available for hormone binding, i.e. the number of cyto-
plasmic receptor sites, would be under the control of two pro-
cesses. Following depletion of receptor sites from the cyto-
plasm by translocation to the nucleus a ''reactivation'' pro-
cess, not requiring protein synthesis, as well as a cyclo-
heximide-sensitive ''synthetic'' process would replenish the 
cytoplasmic receptors. The reactivation process would be trig-
gered only when cytoplasmic oestrogen levels decrease by 50% 
or more, whereas the ''synthetic'' process would account for 
replenishment of smaller amounts of depleted oestrogen 
receptors. Indirect evidence that oestrogens influence the 
concentration of their own receptors comes from experiments 
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in which the receptor levels of target tissue have been 
studied throughout the oestrus cycle. It has been demonstra-
ted that cytoplasmic and nuclear oestrogen receptor levels 
in rat uterine tissue are correlated with the concentration 
of circulating oestrogen (Hawkins et al., 1977; Thrower et 
al., 1977; Myatt et al., 1978; Shih & Lee, 1978). More direct 
evidence on this matter has come from the investigations of 
Sutherland et al. (1977) and Baudendistel et al. (1978), who 
have shown that oestrogens can induce the synthesis of their 
own receptors. 
Prolactin is also thought to be involved in oestrogen 
receptor modulation. The decrease in rat liver oestrogen re-
ceptor following hypophysectomy could be partly prevented by 
prolactin administration (Chamness et al., 1975). In DMBA-
induced rat mammary tumours, prolactin has been found. to in-
crease the number of oestrogen receptors (Leung & Sasaki, 
1975; Sasaki & Leung, 1975; Hawkins et al~, 1977; Asselin & 
Labrie, 1978). No effect of prolactin has been observed on 
uterine oestrogen receptor levels (Asselin & Labrie, 1978). 
Summarizing the data presented in this section, it would 
appear that oestrogen as well as prolactin are capable of in-
creasing oestrogen receptor binding capacity. 
The mammary gland, similar to other oestrogen target 
tissues, contains oestrogen receptors. Sander & Attramadal 
(1968) demonstrated by autoradiography a selective accumula-
tion of intravenously injected radioactive oestradiol in mam-
mary gland epithelium of adult virgin rats and of pregnant 
and lactating rats. Uptake of 3H-oestradiol by isolated 
quiescent rat mammary parenchymal cells has also been demon-
strated (Grubbs & Moon, 1974). Using a more refined autoradio-
graphic technique, Sar & Stumpf (1976) reported that after in 
vivo exposure of mammary tissue from lactating rats to radio-
active oestrogens, the label was present mainly in the nuclei 
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of epithelial cells, of acini and ducts. Wittliff et al. 
(1972) showed that the cytosol of lactating rat mammary gland 
contains a macromolecule which specifically binds 3H-oestra-
diol with high affinity. This protein has a sedimentation co-
efficient Of 8 S at low salt concentrations. This was further 
substantiated by Gardner & Wittliff (1973), who showed that 
the macromolecule was a protein and that the sedimentation 
coefficient changed from 8 S to 4-5 S when the protein was 
brought from a low to a high salt concentration. Leung et al. 
(1976) demonstrated the presence of the oestradiol receptor 
also during the post-lactation involution of the mammary 
gland. Park & Wittliff (1977), using a DNA-cellulose binding 
assay, demonstrated that the cytoplasmic oestradiol receptor 
from lactating rat mammary gland undergoes an oestradiol-
and temperature-dependent transformation analogous to oestro-
gen receptors from other oestrogen target tissues. Unlike 
the uterine oestrogen receptor, however, the mammary gland 
oestrogen receptor did not show a 4 S - 5 S change in the 
sedimentation coefficient upon activation, but remained com-
pletely in the 4 S form. 
The presence of oestrogen receptors, also in non-neo-
plastic mammary tissue, is not generally accepted. From auto-
radiographic experiments, the concentration of oestrogen re-
ceptors appears to be lower in normal, quiescent mammary 
tissue than in mammary tissue from pregnant and lactating 
rats or in mammary tumours (Grubbs & Moon, 1974). In normal 
human mammary tissue and benign mammary tumours, the oestrogen 
receptor concentration was also found to be lower than in 
malignant tumours (Wagner & Jungblut, 1976). This probably 
accounts for the extensive use of stimulated mammary glands 
(lactating or pregnant) in most of the studies discussed 
above. The apparently low oestradiol receptor concentration 
in non-neoplastic, quiescent mammary tissue could, on the 
other hand, also be due to the presence of endogenous 
unlabelled oestradiol, which would compete with the radio-
active oestradiol added to detect the receptor sites (Fishman 
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et al., 1977). This methodologic problem will be dealt with 
in Chapter 5, concerning the .''Estimation of oestrogen receptor 
sites". 
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Chapter 3 
INDUCTION OF MAMMARY TUMOURS IN FEMALE RATS 
It has been suggested that carcinogenesis is a two-step 
process (ReusS: Kidd, 1941; Berenblum, 1947). Initiation of 
transformation of normal cells to latent tumour cells would 
be followed by promotion of proliferation of these cells, 
which would ultimately result in the formation of the actual 
tumour. Initiators of neoplastic transformation are found 
among chemical and physical agents, such as dimethylbenzan-
thracene (DMBA) (Huggins et al., 1959), N-nitroso compound~ 
(Singer, 1979) and ionizing radiation (Kellerer & Rossi, 
1975). Promoters of tumour growth are found among chemical 
agents, immunological and nutritional factors and hormones 
(Sivak, 1979). 
3.2. ~~E~E~~~~~~-2~-~~~-i~~~£~i£~_£f_~~~~~EZ-~~~£~E~-i~ 
!~~~1~-Ee!~-~Y-~~~!E£S~g_eg~_i£~i~igg_Ee~i~!f£g 
The mechanism of the synergistic interaction of oestro-
gens and radiation in rat mammary carcinogenesis is still un-
known. However, the model might be useful as an experimental 
counterpart of human mammary cancer (cf. Chapter 1). There-
fore, it was decided to characterize this model with respect 
to type and dosage of radiation, which will be effective in 
causing mammary tumour formation, as well as with respect to 
the endocrine factors possibly associated with the carcino-
genesis. This tumour model could easily fit the two-step me-
chanism proposed by Berenblum (1947). The primary carcino-
genic transformation would then be initiated by ionizing ra-
diation (Kellerer & Rossi, 1975), whereas oestrogen and/or 
prolactin would promote the further growth of the transformed 
cell(s) and would act as the postulated ''promoters''. As men-
tioned in Chapter 1, the experiments described in this thesis 
will focus on the endocrine aspects (oestrogen receptors, 
prolactin) during carcinogenesis. These experiments were part 
of a larger project on mammary gland carcinogenesis and have 
been carried out in collaboration with the Radiobiological 
Institute TNO, Rijswijk, The Netherlands (Dr. J.J. Broerse, 
Dr. D.W. van Bekkum), where the radiation aspects are 
studied. 
The early studies on the synergistic action of oestrogens 
and ionizing irradiation (Segaloff & Maxfield, 1971; Shella-
barger et al., 1976) were carried out with diethylstilboestrol 
(DES) and X- and neutron-irradiation in Ax C rats. In these 
studies the DES was administered through 20 mg pressed choles-
terol pellets containing 5 mg of DES. In this way Segaloff & 
Maxfield (1971) as well as Shellabarger et al. (1976) were 
able to demonstrate the synergism between DES and radiation 
in rat mammary gland carcinogenesis. The main disadvantages 
to the use of DES are that it has to be used in high doses, 
which cause unwanted side effects, like loss of hair and im-
paired growth, and that DES does not occur in the rat under 
physiological circumstances. In addition, a reliable assay 
for DES in plasma was not available at the time the present 
studies were planned. As possible alternatives to the use of 
DES we considered the use of oestradiol and 17a-ethinyl-
oestradiol (EE). EE, like DES, does not occur physiologically, 
but it might be more relevant than DES, since it is widely 
used in oral contraceptive preparations. 
We have studied the way in which oestradiol and ethinyl-
oestradiol had to be administered to female rats in order to 
achieve a sustained release of oestrogen from the depot re-
sulting in a moderately elevated plasma level of oestrogen 
over a prolonged period of time. The results of these studies 
are given in Appendix Paper I. From these results we conclu-
ded that subcutaneous implantation of oestrogen-cholesterol-
paraffin pellets prepared by melting a mixture of the com-
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pounds would meet our demands for both oestrogens. 
The ultimate goal of animal model studies is to extra-
polate the results to the human situation. When studying 
effects of chemicals, the comparative metabolism of the com-
pounds should be taken into account. In the human female, 
oestrone and oestradiol are readily interconvertible and are 
metabolized mainly to 2-, 6-, 16a- and 166-hydroxylated 
oestrogens, which are secreted into the urine (Fotherby, 
1974). Rats metabolize oestradiol in a similar way, although 
the major route of oestrogen elimination in this species is 
via the bile and the faeces (Ball et al., 1974; Fotherby, 
1974). Metabolism of ethinyloestradiol in the human also in-
volves the hydroxylation reactions mentioned above, but in 
addition, fifteen to eighteen percent of the urinary metabo-
lites of EE are de-ethinylated (Williams et al., 1975). In 
the rat, such de-ethinylation has not been observed (Ball et 
al., 1973; Helton et al., 1977). Furthermore, the conjugation 
of EE in man and rats differs considerably (Ghatei & Fotherby, 
19 79). 
Based on the results of the experiments described in 
Appendix Paper I and the considerations above, we have chosen 
to perform all experiments with oestradiol which was implanted 
subcutaneously in cholesterol-paraffin fused pellets. 
3.3. ~~E~Ei~~~~~-~~-~~~-~~~~££~£~_£f_~~~~~El_£~~£~E~-~~-£~~ 
E~E-~i!~-~i~~£~ll~~~~~~£~E~£~~~ 
The measurement of oestrogen receptors in tissues from 
oestrogen-treated rats is influenced by the occupation of re-
ceptor sites by the oestradiol administered via the pellet. 
Hence a technique had to be devised which would make it 
possible to estimate oestrogen receptors irrespective of the 
receptor occupancy. This technique will be described in 
Chapter 5. ~or proper evaluation of such a technique it was 
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necessary to use tissue which would closely resemble the mam-
mary gland tissue and which would contain oestrogen receptors. 
It was decided to use DMBA-induced mammary tumour tissue for 
this purpose. The DMBA-induced rat mammary tumour was origin-
ally described by Geyer et al. (1951, 1953), Huggins et al. 
(1959, 1961) and Huggins & Yang (1962). The behaviour of this 
tumour in response to therapy closely resembles that of many 
human mammary tumours (Mobbs & Johnson, 1974; Fiebig & 
Schmahl, 1977). 
A small survey of literature data on the carcinogenic 
response of two different rat strains to DMBA is given in 
Table 3.1. Fractionated gastric administration of the carci-
nogen gives a shorter latency period in tumour development 
than a single administration of the total dose (Takizawa, 
1973). Therefore, this approach was tested on rats from three 
different strains. 
Sprague-Dawley rats were obtained from C.R. France S.A., 
St. Aubin-le-Boef, France (F) and from the ''Institut f~r Ver-
suchstierzucht, Hannover, Germany (I.V.H.). Fisher rats were 
bred in our own colony from parents obtained from C.R. France 
S.A., St. Aubin-le-Boef, France. Wistar rats (R-Amsterdam 
substrain) were also bred in our own colony. 
Dimethylbenzanthracene (DMBA) was purchased from Fluka, 
Basel, Switzerland and was dissolved in peanut oil to a con-
centration of 10 mg/ml. Gentle heating was applied when neces-
sary. The carcinogen (10 mg) was administered via a stomach 
tube to 54-61 days old animals under light ether anaesthesia. 
A second and third dose of 10 mg DMBA were given one and two 
weeks later. The animals were palpated weekly and the occur-
rence of tumours was recorded. 
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Table 3. I. 
LITERATURE DATA ON THE INDUCTION OF MAMMARY TUMOURS IN THE RAT WITH DMBA 
strain, 
route of 
administration 
dosage 
schedule 
time between 
first treatment 
and tumour 
appearance 
(months) 
tumour 
incidence 
(7,) 
total number 
of tumours 
(number of 
rats) 
reference 
o/c of rats with 
palpable tumours 
100 
80 
60 
40 
20 
5 10 15 20 
weeks after first treatment 
Figure 3.1. Occurrence of mammary tumours in rats of different 
strains following intra-gastric administration of 
DMBA. 
A-A Sprague-Dawley rats IVH; A-A Sprague-Dawley F; 
•-• Wistar R-Amsterdam. The numbers in parentheses 
the total number of rats for each strain. 
o-o Fisher; 
refer to 
The occurrence of mammary tumours in the rats of differ-
ent strains is depicted in Figure 3.1. From the strains 
tested, rats from the Sprague-Dawley strain give the best 
results when a large number of tumours is required in a rela-
tively short period. In contrast to the rats of the Fisher 
and Wistar strains, all Sprague-Dawley rats developed mammary 
tumours. Sprague-Dawley rats developed 8-15 tumours per 
animal, whereas in the other strains only single tumours were 
observed. In addition, the tumours appeared much faster in 
the Sprague-Dawley rats. Based on these results, we have 
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chosen Sprague-Dawley rats to be the hosts of our DMBA-
induced mammary tumours. Since the mammary tumour incidence 
did not differ for the two Sprague-Dawley strains, rats from 
C.R. France S.A. were used for our further studies, because 
it was easier to obtain these rats than the German rats. 
In this chapter, two models have been described for the 
induction of mammary tumours in the rat. The first model, in 
which mammary tumours are induced by the synergistic action 
of oestrogens and ionizing radiation,will be the subject of 
the studies described in Chapter 6 and Appendix Paper III. 
In this chapter the mode of administration and the nature of 
the oestrogen to be administered have been evaluated. It was 
concluded that administration of oestradiol through choles-
terol-paraffin fused pellets can be used for a sustained re-
lease of oestrogen, resulting in moderately elevated plasma 
oestradiol levels. 
The tumorigenic response of three rat strains to DMBA 
was investigated in order to obtain a large number of mammary 
tumours, required to evaluate an oestrogen receptor assay 
which would not be affected by the presence of endogenous 
oestrogen. After three intra-gastric applications of DMBA, 
Sprague-Dawley rats developed more tumours with a shorter 
latency period than Wistar and Fisher rats. 
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Chapter 4 
MATERIALS AND METHODS 
In Chapter 2 and Appendix Paper I a general outline is 
given of the method for the preparation of the oestrogen 
pellets which were used for implantation. The oestrogen 
pellets used in the experiments to be described in Chapter 6 
were prepared as follows: 
- 5400 mg Paraffin (Merck, Darmstadt, Germany, m.p. 69-73°C) 
were placed in a 20 ml round bottomed tube which was heated 
an oil bath. 
- 1800 mg Cholesterol (Sigma, St. Louis, MO, U.S.A.) were 
added. 
- After homogenization of the melt, 800 mg of oestradiol (a 
gift from Diosynth, Oss, The Netherlands) were slowly 
added. The oestradiol dissolved in the melt under evolution 
of vapour bubbles. 
- The melt was aspirated in silicone tubing ¢ I.D. 3 mm, and 
allowed to cool overnight at room temperature (18-20°C). 
- The steroid-filled tubing was cut in slices of 3 mm with 
the aid of a mould and the tubing was removed from the 
pellets. 
- Pellets weighing 19.5-20.5 mg were selected for implanta-
tion. 
For the total number of 152 pellets the mean weight was 20.11 
~ 0.27 mg (s.d.). It should be noted that cholesterol and 
paraffin were used in a 1 3 ratio (w/w) rather than in a 
10 (w/w) ratio as described in Appendix Paper I, since 
oestradiol dissolved faster in a melt containing a higher 
amount of cholesterol (K.J. van den Berg, personal communica-
tion). This change had no effect on plasma levels of oestra-
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diol measured at different times after implantation (Chapter 
6, Appendix Paper III). 
The total dose of ionizing radiation used was administered 
as a single dose of 2 Gy (200 rad) X-rays. During the irradia-
tion the animals were kept in small nylon containers rotating 
coaxially with the radiation beam axis (Broerse et al., 1978). 
The irradiations were performed by Dr. J.J. Broerse at the 
Radiobiological Institute T.N.O., Rijswijk, The Netherlands. 
For estimation of prolactin levels in the plasma samples, 
a homologous double antibody radioimmunoassay was used, which 
is based on the method described by Kwa et al. (1969). Rabbit 
antisera against rat prolactin and rat prolactin preparations 
for iodination were kindly provided by Dr. H.G. Kwa (Nether-
lands Cancer Institute, Amsterdam, serum K/RP-280) and Dr. 
A.F. Parlow (National Institute of Arthritis, Metabolism and 
Digestive Diseases, Rat Pituitary Hormone Distribution 
Program, N.I.H., Bethesda, MD, U.S.A., serum NIAMD-Anti-Rat 
Prolactin-5-6), who also supplied us with a rat prolactin 
reference preparation (RP-1). 
A commercially available iodinated rat prolactin prepa-
ration (New England Nuclear, Dreieich, Germany) was used as 
a tracer in the prolactin assay. The specific activity of 
this preparation was 42. I ~ 1.4 vCi/vg (mean~ s.e.m., n = 6). 
Immediately upon arrival the label was diluted to a final 
concentration of 10,000 cpm/50 vl (0.5 ng) with 0.1% Bovine 
Serum Albumin (BSA) in 0.01 M phosphate-buffered saline (PBS) 
pH 7.6, containing 0.05% iodium azide. Stock solutions (1%) 
of antisera were prepared in PBS, containing 0.25% Normal 
Rabbit Serum (NRS). Working solutions of the antisera were 
prepared by dilution of the stock solutions with 1% NRS in PBS. 
Stock solutions of the reference preparation (RP-1) were 
prepared in PBS, containing I% BSA. This buffer was also used 
to adjust the final volume in the assay tubes to 0.8 ml. 
Precipitation of the antigen-antibody complexes was 
achieved by incubation with 0.2 ml of a 5% solution of Donkey 
Anti Rabbit serum (Wellcome, Beckenham, U.K.) in PBS 
containing 0.5% BSA. The supernatant was separated from the 
precipitate after centrifugation at 4°C for 30 min at ISOOxg 
in a MSE PL-100-A Coolspin centrifuge. The precipitate was 
washed once with ice-cold PBS and counted in a Searle Model 
1195 gamma-counter. All incubations were performed at 6°C. 
Incubation periods of 48 hours with the first antibody, and 
24 hours with the second antibody were used. 
The binding of the label to different dilutions of the 
antisera was evaluated. The results are depicted in Figure 
4. 1. From these results it was concluded that the titer of 
the K-RP-280 serum was 4 times higher than that of the NIH-
S-6 serum. Routinely, the K-RP-280 was used in a I 10,000 
dilution (final dilution 1 40,000). Standard curves were 
constructed with 0.8- SOng of RP-1. The label is displaced 
from the antiserum by prolactin in rat plasma and pituitary 
cell culture medium in a dose-dependent way, parallel to RP-1 
(Figure 4.2). Samples were assayed in at least four dilutions. 
The amounts of prolactin in the samples were calculated from 
the linear part of the ln-logit transformed standard curve~. 
Characteristics of the performance of the prolactin radio-
immunoassay are given in Table 4.1. 
Prolactin levels in plasma obtained at 09.00 h from our 
Sprague-Dawley rats throughout the oestrus cycle are shown in 
Figure 4.3, together with the oestradiol levels, which were 
assayed with the method described by DeJong et al. (1973). 
~The computer program was written by W.F. Clotscher (Depart-
ment of Biochemistry II, E.U.R.). 
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Table 4.1. 
Characteristics of rat prolactin radioimmunoassay (means + 
s.e.m., n""' 8). 
% initially bound tracer (B
0
) 
mass at 50% inhibition 
correlation co~fficient standard curve 
intra-assay variation 
inter-assay variation 
% 125 1-PRL bound 
80 
70 
60 
~ ---------------
40 
30 
20 
10 
5 I + 
2.0 + 0.2 ng RP-1 
0.995 + 0.001 
4.7 + 1.2% 
14.9% 
Antiserum dilution factor 
F . 4 I A . . . " h 125 r 1 . ~gure . . nt~serum t~trat~on curves w1t -pro act1n 
(l25I-PRL). o---o NIH-S-6, •---• K-RP-280. Results 
are means+ s.d. (n = 4). The abcissa gives the dilution of 
antisera added to the tubes; the final dilution in the tubes 
is 4 times as high. 
40 
0M 125 1-PRL bound 
50 
II 
• 40 
30 
20 
10 
0 
0.5 2 5 10 "I P.C.M 
0 0.5 2 5 10 20 50 100 200 ng RP1 
!JI plosmo 
Figure 4.2. Displacement of 1251-prolactin ( 125 1-PRL) bound 
to 1 : 40,000 diluted K-RP-280 antiserum by RP-1 
(•---•), rat plasma (o---o) and pituitary culture medium 
(PCM) (1>-b). 
DNA was estimated by the method of Giles & Myers (1965) 
in nuclear pellets, extracted with 0.4 M KCl, obtained from 
mammary gland tissue (Chapter 5). The pellets were dissolved 
in 1 N KOH by heating to 60°C for 30 minutes. Remaining fat 
was separated from the solution by centrifugation at 30,000xg 
for 30 min. The fat-free solution was obtained by piercing 
the bottom of the centrifuge tubes and aspirating the solu-
tion. DNA and protein were precipitated by incubation with 
1 ml 1.2 M perchloric acid for 30 min at 6°C. Subsequently, 
the DNA was hydrolized by heating the tubes for 15 min at 
70°C. To all tubes 1.2 ml of 3% diphenylamine solution and 
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E2 (pg/ml) 
80 
60 
40 
20 
PRL (ng/ml) 
301 
20 
10 
p 0 M 
Oestrus cycle stage 
Figure 4.3. Plasma oestradiol CE2) and prolactin (PRL) in 
Sprague-Dawley rats at 09.00 h at different days 
through the oestrus cycle (results are means + s.e.m., n = 5). 
P = proestrus; 0 = oestrus; M = metoestrus; Dj = dioestrus-
day I; D2 =dioestrus-day 2. 
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50 ~1 of 0.16% acetaldehyde were added. The tubes were incu-
bated for 18 h in the dark and after centrifugation for 10 
min at lOOOxg the extinction at 595 nm was estimated. Calf 
thymus DNA (Sigma, St. Louis, U.S.A.) was used as a standard. 
Broerse, J.J., S. Knaan, D.W. van Bekkum, C.F. Hollander, 
A.L. Nooteboom and M.J. van Zwieten (1978) In: Proc. 
Int. Symp. on the late biological effects of ionizing 
radiation, IAEA-SM-224/202, Vol. II, pp. 13-27. 
Giles, K.W. and A. Myers (1965) Nature 206, 93. 
Jong, F.H. de, A.H. Hey and H.J. van der Molen (1973) 
J. Endocr. 12· 277-284. 
Kwa, H.G., A.A. van der Gugten and F. Verhofstad (1969) Eur. 
J. Cancer~. 559-569. 
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Chapter 5 
ESTIMATION OF OESTROGEN RECEPTOR SITES 
Part of our studies concerned a possible role of oestro-
gen receptors in the mechanism of oestrogen-stimulated carci-
nogenesis of rat mammary gland. In this respect it was neces-
sary to estimate the content of oestrogen receptors in mammary 
glands of normal virgin rats. Since some groups of rats to be 
studied received exogenous oestradiol (Chapter 3), such are-
ceptor assay should be independent of the amount of ''endoge-
nous" oestradiol present in the mammary tissue. In addition, 
it should be possible to measure nuclear receptors since at 
least part of the receptors was expected to be present in 
the nuclear compartment. Furthermore, the assay should permit 
to reach unequivocal conclusions about the possible presence 
of oestrogen receptors in normal mammary glands of adult vir-
gin rats, which had not been demonstrated previously. 
The experiments to be described in this chapter have 
been carried out with the purpose: 
I) to demonstrate the presence of oestrogen receptors in 
normal virgin rat mammary glands; 
2) to develop an oestrogen receptor assay for the measurement 
of total (free and occupied) oestrogen receptors in nuclear 
preparations of DXBA-induced rat mammary tumours and 
3) to evaluate whether oestrogen receptors, present in normal 
rat mammary tissue, could be estimated routinely with this 
assay. 
Receptors for steroid hormones are frequently measured 
by incubation of tissue or tissue fragments with a saturating 
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dose of radioactive steroid to label the receptors with 
steroid. Receptor-bound and free steroid are then separated 
and the amount of binding sites is calculated from the amount 
of receptor-bound radioactivity. In addition to binding to 
specific, high-affinity, low-capacity receptors, steroids can 
be bound also by non-receptor proteins (cf. Chapter 2). Such 
non-receptor proteins usually have a lower affinity and a 
larger capacity for binding of steroids and this type of 
binding is generally termed ''aspecific binding''. In assaying 
the amount of specific receptors, a correction has to be made 
for the aspecific binding. 
In our experiments we have used parallel incubations 
with a 100-200 fold excess unlabelled oestradiol to correct 
for aspecific binding. Since steroid receptors have a low 
binding capacity, the amount of receptor-bound radioactivity 
in the second incubation will be very small. The non-receptor 
binding proteins generally have a high capacity, hence the 
amount of ''aspecifically'' bound radioactivity will not be 
decreased in the second incubation. The amount of receptor-
bound radioactivity is then determined as the difference of 
the results of the two incubations. Clearly, this type of 
correction is only valid as long as the excess non-radioactive 
steroid is not saturating the non-receptor binding sites 
(Chamness & McGuire, 1976). 
5.3. ~~~£g~~E~~~£g_£f_£l~£E!~~~~£_£~~~E£g~g_E~£~E~£Ee_~g 
~~~~~El_!~~~~~-fE~~-~~~l!_~iEBi~-E~!~ 
The presence of oestrogen receptors in mammary glands of 
lactating rats and in rat mammary tumours is supported by 
autoradiographic and biochemical evidence (see section 2.6) 
For the resting mammary gland in virgin rats, there is only 
autoradiographical evidence which suggests uptake of oestro-
gens in epithelial cells (Sander & Attramadal, 1968; Grubbs 
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& Moon, 1974). Biochemical evidence for the presence of 
oestrogen receptors in normal resting mammary tissue has not 
been reported yet. The results of Kothari et al. (1977) sug-
gested the presence of very small amounts of oestrogen 
receptor in the cytosol from mammary glands of young rats. 
They could not demonstrate, however, the presence of the re-
ceptor in cytosols from 140 days old or older animals. This 
negative result might have been caused by occupancy of the 
receptor sites by endogenous oestradiol, especially since the 
level of oestrogen receptors in cytosols of uterine tissue 
from intact rats as reported by these authors was also very 
low. 
Since our studies were designed to evaluate the possible 
role of oestrogen receptors in carcinogenesis of the mammary 
glands of adult virgin rats, the absence or presence of re-
ceptors in the mammary glands at risk had to be demonstrated. 
Cytoplasmic oestrogen receptors were measured in tissues 
from animals which were ovariectomized 3 days before the 
experiments to avoid receptor occupancy by endogenous oestra-
diol. Mammary and uterine tissues were isolated from the de-
capitated animals and were immediately immersed in liquid 
nitrogen. Tissues were homogenized in a chilled (-190°C) 
Mikrodismembrator vessel (B. Braun, Melsungen, Germany) for 
45 s at maximum amplitude. Two volumes of 0.01 M Tris-HCl 
buffer containing 0.0015 M EDTA and 0.02% sodium azide (w/v) 
were added to the powdered tissue. After thawing at 0°C the 
tissue was suspended in the buffer by vortex mixing. The 
cytosol was obtained by centrifugation 
The cytosol was incubated overnight at 
of 3H-oestradiol either in the absence 
at 100,000 
0°C with 2 x 
x g at 
10- 9 M 
or presence of 
-7 4 x 10 M unlabelled oestradiol. Separation of bound and 
free steroid was achieved by agar-gel electrophoresis 
according to Wagner (1972). The gel was sliced and the amount 
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of radioactivity was determined in the individual slices (Van 
Beurden-Lamers et al., 1974). 
The results in Figure 5.1 demonstrate the presence of 
oestrogen receptor sites in the cytosols of uterine and mam-
mary tissue from ovariectomized rats. Like Kothari et al. 
(1977) we were not able to demonstrate the presence of oestro-
gen receptors in th0 cytosol of mammary tissue from intact 
rats. This is probably due to the occupancy of oestrogen re-
ceptors by endogenous oestradiol and concomitant transloca-
tion of the receptors to the nuclear compartment. Therefore, 
the cytoplasmic oestrogen receptor assay was considered 
inadequate for a proper assessment of oestrogen receptors in 
intact and oestrogen-treated virgin female rats which had to 
be used for the evaluation of the possible role of oestrogen 
receptors in rat mammary carcinogenesis. 
5.4. ~~~~Y_£f_~~£!~~E_£~~~E£g~~-E~£~E~£E~-i~-~~~~~EY-~i~~~~ 
~~-~~~1£-~i!Ei~-E~£~ 
I~ receptors are involved in the biochemical mechanism(s) 
of steroid action(s), it may be expected that nuclear 
receptors are closest to the site of action on the DNA/ 
chromatin. In this respect, the nuclear exchange technique 
may be the most advanced and theoretically most attractive 
technique for receptor assay. In this type of assay, free 
oestrogen receptors in the cytoplasm are translocated to the 
nuclei either in vitro or in vivo by unlabelled oestradiol. 
After isolation of a nuclear fraction the unlabelled oestra-
diol is exchanged with 3H-oestradiol and receptors are quan-
tified. Different investigators have used variety of 
exchange conditions for the assay of oestrogen receptors in 
normal and neoplastic tissues as summarized in Table 5.1. 
Also for the separation of receptor-bound and free steroid 
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Figure 5.1. Oestrogen receptors in tissues from ovariectomized 
adult female rats. 
Agar gel electrophoretic pattern of radioactivity in uterine 
and mammary tissue cytosols after incubation with 2 x JQ-9 M 
3H-oestradiol, either in the absence (•--•) or presence 
(o---o) of 4 x JQ-7 M unlabelled oestradiol. The arrows mark 
the application sites of the samples on the agar gel. Free 
steroids move to the cathode (-) whereas receptor-bound 
steroid migrates towards the anode (+). 
different methods have been used (Table 5. I). The only method 
which, in addition to quantitative information, also gives a 
positive identification of the receptor is the nuclear ex-
change assay described by De Boer et al. (1977). In this 
method oestrogen receptors are identified by their sedimenta-
tion characteristics on sucrose gradients. We have evaluated 
whether this method could also be applied to the estimation 
of oestrogen receptors in rat mammary tissues. As a source of 
tissue we have used the DMBA-induced rat mammary tumour 
(section 3.3), since these tumours contain oestrogen receptors 
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"' 0 ~-~~· Nuclear exchange assays for oestrogen receptors in different target tissues 
--------------------
Reference 
Anderson et al. (1972) 
Zava et al. ( 1976) 
De Boer et al. (1977) 
Tsai & Katzenellenbogen 
(1977) 
Nicholson et al. (1977) 
Laing et al. (1977) 
Souter et al. (1979) 
Tissue 
immature rat 
uterus 
rat uterus 
immature rat 
uterus 
immature rat 
testis 
rat uterus 
rat DNBA-
tumour 
rat DHBA-
tumour 
human mammary 
carcinoma 
human endo-
metrium 
Nuclear 
preparation 
800xg pellet 
protamine sulphate 
precipitated 0.6 H 
KCl extract of 
800xg pellet 
800xg pellet 
500xg pellet 
800xg pellet 
800xg pellet 
800xg pellet + 
protamine sulphate 
5000xg pellet 
700xg pellet 
Exchange;: 
conditions 
h 37°C TE-buffer 
2 h 37°C TED-buffer 
I h 
25% 
37°C TEA-buffer l 
glycerol (v/v) 
15 min 20°C TEA-buffer 
25% glycerol (v/v) 
45 min 30°C TE-buffer 
4 h 15°C TE-buffer 
45 min 30oc 
2 h 15°C TED-buffer 
18 h 4°C 0.15 H NaCl 
18-24 h 4-10°C, 
0.15NaCl 
;:The abbreviations used in the description of the exchange buffers are: 
T: Tris-HCl 0.01 N; E: EDTA 0.0015 H; D: dithiotreitol; A: sodium azide. 
Isolation of labelled 
steroid-receptor 
complex 
ethanol extraction 
ethanol extraction 
0.4 H KCl extraction 
and sucrose gradient 
centrifugation 
ethanol extraction 
ethanol extraction 
ethanol extraction 
not specified 
filteration over 
Hillipore filters 
and are readily available as a source of mammary epithelial 
tissue. The results of this evaluation are described in Ap-
pendix Paper II. The results show that the oestrogen receptor 
in DMBA-induced rat mammary tumours is unstable when kept at 
elevated temperatures for long periods. At elevated tempera-
tures dissociation of steroid-receptor complexes will occur 
at a higher rate, whereas degradation may be kept to a mini-
mum when a short incubation time is used. Exchange at 23°C 
for 15 minut~s was shown to give the same results as exchange 
at 0-6°C for l hour or more. For routine purposes we have 
used an exchange temperature of 0-6°C. 
For the application of the nuclear exchange assay to the 
estimation of oestrogen receptors in normal (non-neoplastic) 
rat mammary tissue, a slight modification of the assay proce-
dure had to be introduced. For uterine and DMBA-tumour tissue, 
translocation of oestrogen receptor sites to the nuclei was 
successfully achi2ved by incubation of minced tissue with 
10- 8 M unlabelled oestradiol as described in Appendix Paper 
II. In non-neoplastic mammary tissue, however, the transloca-
tion could not be achieved in this way. This was probably 
caused by the presence in the virgin rat mammary gland of 
massive amounts of fat cells, which may inhibit proper pene-
tration of the oestradiol into the tissue. This problem was 
circumvented by the use of in vivo translocation of 
receptors. Animals were injected subcutaneously with 25 ~g 
of oestradiol. At the time of sacrifice, h later, a plasma 
oestradiol level of 7.5 + 1.0 ng/ml (mean~ s.e.m., n • II) 
was reached. In this way, nuclear receptors could be detected 
in the mammary glands of adult virgin rats, whereas cytoplas-
mic receptors were undetectable. With this modification the 
amount of oestrogen binding sites in mammary gland tissue of 
normal adult virgin rats was estimated to be 64 + 9 £moles/ 
mg protein in the nuclear extract (mean~ s.e.m., n = 6). 
To demonstrate that the oestrogen receptor in normal rat 
mammary tissue is heat-sensitive, similar to the receptor in 
DMBA-tumour and uterine tissue (Appendix Paper II), we incu-
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Figure 5.2. Instability of the oestrogen receptor from mam-
mary glands of virgin rats at room temperature. 
Rats were injected with 25 ~g of oestradiol 1 hour prior to 
3acrifice. Nuclear suspensions of mammary tissue were incu-
'...J.s.ted for 18 h at 60C (•--•) and 19oc (o--o) with to-8 ~i 3H-
o~stradiol. The gradient profiles obtained after incubation 
~i:h 100-fold excess unlabelled oestradiol coincided with the 
~rofile for the 190C incubation. 
bated nuclear suspensions of normal mammary tissue for 18 h 
at 6°C and l9°C. The results in Figure 5.2 indeed show that 
the oestrogen binding capacity is destroyed after incubation 
at room temperature. For the assay of oestrogen receptors in 
normal rat mammary tissue we therefore also adopted 18 hand 
0-6°C as standard conditions for the nuclear exchange. 
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Figure 5.3. Flow-chart for exchange assay of nuclear oestro-
gen receptors. 
A schematic outline of the method used is illustrated in 
Figure 5.3. 
To further evaluate the nuclear exchange assay used, 
minced uteri of ovariectomized animals were incubated for 
1 hour with either 10-S M 3H-oestradiol (direct labelling of 
-8 
receptors) or 10 M unlabelled oestradiol. Nuclear suspen-
sions were prepared and 3H-oestradiol-receptor complexes 
were extracted with 0.4 M KCl from the suspension obtained 
from the tissue incubated with 3H-oestradiol. The nuclear 
suspension obtained from the tissues that were incubated with 
radioinert oestradiol were incubated overnight at 6°C with 
10-B M 3H-oestradiol to exchange the receptor-bound oestra-
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diol. After exchange a nuclear extract was prepared. Oestrogen 
receptors were estimated by protamine-sulphate precipitation 
and protein and DNA were measured in the extracts and the 
pellets respectively. The results of this experiment are pre-
sented in Table 5.2. Both receptor assays yield identical 
results when the binding was expressed as fmoles bound 
steroid/mg protein (P) in the nuclear extract. When the 
binding was expressed as fmoles/mg DNA in the pellet, the 32% 
decrease in the estimated DNA content after the exchange incu-
bation resulted in a significantly higher estimated receptor 
level after exchange. 
Table 5.2. 
Comparison of exchange assay vs. direct labelling for estima-
tion of nuclear oestrogen receptors in uteri from ovariecto-
mized rats (means+ s.e.m. (n)). 
parameter exchange direct p~ 
!2i!!2;i!!:S 
total (fmole/mg P) 356+ 12 ( 3) 302+ 29 ( 3) N.S. 
aspec. (fmole/mg P) 95+ 4 ( 3) 41+0.3 (3) <0. 01 
spec. (fmole/mg P) 261+ 13 (3) 261+ 29 ( 3) N.S. 
total (fmole/mg DNA) 3943+228 (3) 2170+290 ( 3) <0. 01 
aspec. (fmole/mg DNA) 1063+ 72 ( 3) 260+ 21 (3) <0.01 
spec. (fmole/mg DNA) 2880+150 ( 3) 1920+270 (3) <0. 05 
Pellet DNA (vg) 215+ 8 ( 6) 317+ 23 ( 6) <0.01 
Extract protein (mg/ml) 2.39+0.02 ( 6) 2.11+0.07 ( 6) <0. 01 
*student's t-tes t. 
The results in Table 5.2 suggest that the exchange pro-
cedure influences the DNA content of the nuclear pellet more 
54 
than the protein content of the nuclear extract. The most 
probable explanation for the observed effect appears to be 
that, during the exchange, some of the DNA, either intact or 
split by nuclease, goes into solution and is discarded to-
gether with the exchange medium. Also during the extraction 
of the nuclear pellet, some DNA may dissolve in the nuclear 
extract. To test this hypothesis, nuclear suspensions were 
prepared from mammary and uterine tissue, either directly (I) 
or after incubation of minced tissue for hat 37°C (II). 
The suspensions obtained from the tissue which was not incu-
bated (I) were incubated overnight at 6°C in exchange medium. 
All nuclear suspensions were extracted with 0.4 M KCl and DNA 
was estimated in the exchange media, nuclear extracts and 
pellets. The results in Table 5.3 indeed show that DNA is 
lost in the exchange and extraction buffers. 
Table 5.3. 
Loss of DNA from mammary and uterine nuclear pellets during 
exchange and direct labelling assays for nuclear oestrogen 
receptors 
Assay Fraction 
DNA-content in different fractions 
(%, mean~ s.d., n = 3) 
Mammary Gland 
direct nuclear pellet 83.7 + 2. 3 
nuclear extract I 6. 2 + 2. I 
exchange nuclear pellet 6 2. 4 + 2.5*:!:: 
< 
< 
exchange medium 19. 5 + 4. 4 
nuclear extract 18. 0 + I . 9 
0.05 vs. incubation of minced tissue 
0.05 vs. mammary tissue 
Uterus 
96.2 + 0.7~ 
3.8 + 0.7~ 
57.2 + 6.8"~ 
I 6. 7 + I . 3 
25.9 + 6.7** 
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From the results of the experiments described in this 
chapter and in Appendix Paper II the following conclusions 
were obtained: 
1) Oestrogen receptors are present in mammary tissue of 
adult virgin rats. 
2) The rat uterine oestrogen receptor can dissociate its 
ligand at a low temperature, similar to the mammary gland 
oestrogen receptor. 
3) The DNA content of nuclear pellets from mammary and uterine 
pellets is significantly lower after exchange assay than 
after direct labelling assay for nuclear oestrogen 
receptors. 
4) The oestrogen receptors in rat mammary tissue can be esti-
mated with the low-temperature nuclear exchange assay 
described in Appendix Paper II, provided that oestradiol 
was administered in vivo rather than in vitro for trans-
location of receptor sites from the cytoplasm to the 
nucleus. 
This is the first report in which the presence of oestra-
diol receptors in mammary glands of adult virgin rats has 
been demonstrated biochemically. Earlier attempts of Kothari 
et al. (1977) failed, which is in agreement with our experi-
ments carried out in the presence of endogenous oestradiol. 
In tissue from intact rats, receptors could only be demon-
strated with the use of the nuclear exchange assay and after 
in vivo translocation of the receptors from the cytoplasm to 
the nucleus. Therefore, it appears that many, if not all, 
oestrogen receptors in mammary glands are normally occupied 
with endogenous oestradiol. 
The observation that mammary gland, mammary tumour and 
uterine oestrogen recaptor~ can exchange their ligand even at 
low temperatures, is in contrast to the results of Anderson 
et al. (1972), Zava et al. (1976), De Boer et al. (1977), 
Nicholson et al. (1977), Tsai & Katzenellenbogen (1977) and 
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Souter et al. (1979). The observations of Laing et al. (1977) 
with human mammary tumours and of Traish et al. (1979) with 
isolated rat uterine cells are in agreement with our observa-
tions. The reason for this discrepancy is still unclear. It 
has been suggested that the use of Triton in the preparaticn 
of the nuclear pellets might cause the effect, since Triton, 
even at low concentrations, would increase the dissociation 
constant of the oestrogen-receptor complex (W. de Boer, pri-
vate communication, 1979). Preliminary experiments, however, 
have shown that the exchange of the steroid from the uterine 
oestrogen receptor occurs also if Triton is omitted from the 
buffer used to wash the nuclear pellet. This could be ex-
plained if the receptor were protected fro~ the Triton as 
long as it is incorporated in the nuclear pellet. Hence, it 
appears unlikely that the dissociation of the oestrogen-
receptor complex at low temperatures is caused by the use of 
Triton. 
The results in Tables 5.2 and 5.3 show that DNA is lost 
from the nuclear pellet during the exchange procedure. Since 
DNA is thought to play an essential role in nuclear binding 
of the steroid-receptor complex, it is peculiar, that no 
concomitant decrease in oestrogen receptor concentration was 
observed (Table 5.2). When a comparison was made between 
mammary gland oestrogen receptor concentrations express~d 
per mg of protein in the nuclear extract and per ~g of DNA in 
the nuclear pellet, a statistically significant correlatiou 
was observed (r = 0.667, n = 31, p < 0.01). In view of the 
data in Tables 5.2 and 5.3, it is unclear whether this sta-
tistical significance reflects a true biological significance. 
Therefore, we have expressed the oestrogen receptor level 
relative to the protein concentration in the nuclear extract 
(Chapter 6 and Appendix Paper III). 
The nuclear exchange assay described in this chapter 
yields the same results as the in vivo assay in which tritia-
ted oestradiol was injected in ovariectomized animals tAppen-
dix Paper II). Therefore, we have concluded that the nuclear 
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exchange assay is suitable for the estimation of oestrogen 
receptors in tissues from intact animals. 
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Chapter 6 
RAT MAMMARY GLAND OESTROGEN RECEPTORS AND PLASMA PROLACTIN 
DURING MAMMARY CARCINOGENESIS INDUCED BY OESTROGEN AND 
RADIATION 
Oestrogens and ionizing radiation can act synergistically 
in the development of mammary tumours in female rats (Segaloff 
& Maxfield~ 1971; Shellabarger et al., 1976; Broerse et al., 
1978). The mechanism through which oestrogens enhauce 
radiation-induced mammary carcinogenesis has not been eluci-
dated yet. It is generally accepted that oestrogens exert 
their effect(s) on target tissues through specific receptors 
(cf. Chapter 2). Oestrogens can influence the synthesis of 
oestrogen receptors (Sarff & Gorski, 1971; Mester & Baulieu, 
1975) and oestrogens are also known to stimulate pituitary 
prolactin release (Chen & Meites, 1970). From these observa-
tions at least two mechanisms could be considered to explain 
the effect of oestrogens in rat mammary tumour development. 
Firstly, oestrogens could influence their interaction with 
the mammary tissue through inducing the synthesis of their 
own receptors. Secondly, since prolactin appears to play a 
major role in mammary tumour development in the rat (Meites, 
1972), oestrogens could exert their co-carcinogenic action 
via an increase in the prolactin concentration in the plasma. 
The experiments described in this chapter were performed 
to relate the synergistic interaction of oestrogen and ioni-
zing radiation in rat mammary tumour development with possible 
changes in the content of nuclear oestrogen receptors in the 
mammary glands and the plasma prolactin concentration. For 
this purpose, nuclear oestrogen receptors were estimated with 
the nuclear exchange assay, described in Chapter 5 and Appen-
dix Paper II, in mammary tissue of female rats for a period 
of 14 months after administration of 2 mg of oestradiol 
(Chapter 3) and exposure to 2 Gy of X-rays. As a result of 
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this treatment, approximately 50% of the rats was expected to 
develop mammary tumours (Broerse et al., 1978). Prolactin was 
estimated in the plasma of the same rats. 
The results, described in Appendix Paper III, revealed 
that oestradiol administration caused a decrease in the 
oestrogen receptor content of the mammary glands and an in-
crease in the plasma prolactin concentration. Radiation had 
no additional effsct on the parameters studied. During the 
progress of the experiments it appeared that as a result of 
the treatment regimen used in the present study, 50% of the 
rats could be expected to develop a mammary tumour. In 
addition, it turn~d out that the synergistic interaction of 
oestrogens and radiation in mamma~y tumour development applies 
only to malignant tumours which accounted for 50% of the 
total tumour incidence (Van Eekkum et al., 1979). It could 
be envisaged, that the expected increase in the oestrogen 
receptor content of the mammary tissue occurs only in those 
rats which ultimately would develop a malignant mammary 
tumour (25%). A concomitant decrease in the oestrogen receptor 
~ontent of mammary tissue of rats which will not develop such 
tumours could then result in the observed decrease in the 
mean receptor concentration. If this were true, the frequency 
distribution of the estimated oestrogen receptor levels 
should show the existence of two populations of rats, one 
with a low, and the other with a high content of oestrogen 
receptors in the mammary tissue. The actual frequency distri-
bution, which is shown in Figure 6.1, does not indicate the 
existence of two such populations. In contrast, the results 
in Figure 6.1 once more reflect the general decrease of the 
estimated content of oestrogen receptors of the mammary 
tissue observed in oestrogen-treated rats. 
The decrease in the oestrogen receptor content of the 
mammary tissue and the increase in the prolactin concentration 
of the plasma observed in oestradiol-treated rats occur well 
before mammary tumours become manifest (Broerse et al., 1978). 
Therefore it is suggested, that oestrogens exert their cocar-
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Figure 6.1. Frequency (f) of oestrogen receptor contents 
estimated in mammary tissue of control rats and 
of rats treated with oestradiol and/or radiation, from 2-14 
months after treatment. 
cinogenic effect, if any, through either or both of these 
changes. 
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CHAPTER 7 
GENERAL DISCUSSION 
The experiments described in the preceding chapters were 
carried out in an attempt to detect possible changes in the 
number of oestrogen receptors in mammary tissue and in plasma 
prolactin before mammary tumours become macroscopically mani-
fest. It was hoped to obtain more insight in the suggested 
role of oestrogens (Segaloff & Maxfield, 1971; Shellabarger et 
al., 1976; Broerse et al., 1978; Segaloff & Pettigrew, 1978; 
Van Bekkum et al., 1979; Holtzman et al., 1979) and prolactin 
(Meites, 1972; Welsh & Nagasawa, 1977) in the mechanism of 
mammary gland carcinogenesis. The experiments described in this 
thesis differed from the approach which is generally used, in 
that the parameters under study were estimated during the pro-
cess of carcinogenesis, and not after the tumours had developed. 
The model system used was the oestrogen- and radiation-induced 
rat mammary cancer as discussed in Chapters and 3. This model 
appeared also relevant for the human situation, because of the 
possibility that the risk for human females to develop mammary 
cancer might increase as a result of more frequent exposure to 
ionizing radiation in diagnostic medicine (Upton, 1975) and the 
concomitant use of oestrogen-containing oral contraceptives by 
an increasing number of females (Rinehart & Piotrow, 1979). 
The main conclusions from the results described in Chapter 
6 and Appendix Paper III show, that after oestrogen and radia-
tion treatment the oestrogen receptor content of mammary tissue 
was decreased and plasma prolactin concentrations were 
increased. These changes are the result of the administration 
of exogenous oestradiol, and occur well before mammary tumours 
are known to develop in these animals. It was suggested that 
oestrogens exert their effect(s) in tumour development through 
either one or both of these changes. It has been shown, that 
oestradiol as such is not carcinogenic in the Sprague-Dawley 
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rats used in the present study (Van Bekkum et al., 1979). 
Prolactin is known to stimulate the growth of mammary tumours 
in the rat (Meites, 1972). Therefore, oestradiol might exert 
at least part of its enhancing effect in radiation-induced 
mammary carcinogenesis through an increased prolactin secre-
tion. 
In the first section of this chapter the possible invol-
vement of oestrogen receptors in mammary tumour development 
will be discussed. In subsequent sections, the model system 
used will be evaluated, and a comparison of rat and human 
mammary cancer will be made. 
7.1. !Q~_E£~~i£!~_E£!~_£f_£~~£E£8~~-E~£~E££E~-i~-E~£-!e!~eEY 
!~~~~E-~~~~!£E~~~! 
Based on the generally accepted mechanism of steroid 
hormone action (Chapter 2), several mechanisms could be sug-
gested for the involvement, if any, of oestrogen receptors in 
the co-carcinogenic action of oestrogens on mammary tissue. 
Firstly, the continuous release of oestradiol from the 
pellet implanted might cause the receptors in the mammary 
tissue to be permanently translocated into the nuclear com-
partment. The expression of the effects of oestrogens might 
depend on the period during which the oestradiol-receptor 
complex is bound to the chromatin. It has been suggested, for 
instance, that anti-oestrogens act initially as oestrogens in 
translocating cytoplasmic receptors to the nucleus~ and that 
the anti-oestrogenic effect of these compounds would reside 
in their capability to prolong the retention of the receptor 
in the nucleus and thus interfere with the recycling of the 
receptors from the nucleus to the cytosol (Clark et al., 
1973; Katzenellenbogen et al., 1977). If the continttous pre-
sence of oestradiol in our rats would have resulted in a con-
tinuous nuclear localization of the receptors in the mammary 
tissue, thus interfering with the proper recycling of the 
receptors to the cytoplasm, then oestradiol would be able to 
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diminish its own effect on mammary tissue. Evaluation of 
these suggestions will require detailed knowledge of the pro-
cessing of nuclear oestradiol-receptor complexes, which is 
presently not available. 
A second possibility for the involvement of oestrogen 
receptors in mammary carcinogenesis could be that oestrogens 
influence the synthesis of oestrogen receptors in the tissue 
at risk. From the results obtained in relatively short-term 
experiments reported by Sarff & Gorski (1971) and Mester & 
Baulieu (1975), it was suggested (Chapter 2) that oestrogens 
can stimulate the synthesis of oestrogen receptors in the 
mammary tissue. It appears from the results reported in 
Chapter 6 and Appendix Paper III, however, that this does not 
apply for long-term experiments, such as used in the present 
study. A decrease was observed in the mammary gland oestrogen 
receptor content, whereas the uterine receptor content was 
not affected. Katzenellenbogen et al. (1977) suggested from 
their studies on the mechanism of action of anti-oestrogens, 
that prolonged retention of oestrogen receptors in the nucleus 
could not only interfere with the recycling of receptors, but 
also prevent~ novo synthesis of receptors. This situation 
might also prevail in the mammary tissue of the rats in our 
study. 
Finally, since normal mammary tissue is considered to 
contain less oestrogen receptors than mammary tumour tissue 
(Wagner & Jungblut, 1976), the effect of oestrogens on mam-
mary tumour development might be mediated through a specific 
increase of the receptor content of cells in preneoplastic 
tissue or in microtumours. This suggestion of Wagner & 
Jungblut (1976), however, was based on measurements of cyto-
plasmic receptors, rather than nuclear or total receptor con-
tent. This possibility is supported by the observation that 
in the cytosol of normal mammary tissue from intact adult' 
female rats no oestrogen receptors could be detected (Kothari 
et al., 1977: Chapter 5), whereas rat mammary tumours do con-
tain receptors in the cytoplasm (Nicholson & Golder, 1975). 
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Using the nuclear exchange assay described in Chapter 5, it 
was possible to demonstrate the presence of oestrogen 
receptors in normal mammary tissue as well as in mammary 
tumours (Chapters 5 and 6). The oestrogen receptor level in 
DMBA tumours appears to be comparable to that measured in 
normal mammary tissue, when expressed relative to the protein 
concentration in the nuclear extract. Also in tumours induced 
with oestradiol and radiation, the receptor content, 19 + 7 
fmoles/mg nuclear extract protein (mean~ s.e.m., n ~ 8, 
range 4-60), does not exceed that of normal mammary tissue. 
It would be of interest to compare with the nuclear exchange 
assay the oestrogen receptor content of human mammary tumours 
to that of normal mammary tissue. The suggestion, that oestro-
gen treatment would cause an increase in receptor levels spe-
cifically in preneoplastic or microtumour cells, is not con-
sistent with the considerations given above, nor with the 
overall decrease in receptor content of the mammary tissue as 
reported in Chapter 6. Such a specific increase in receptor 
levels also would result in an inhomogenous frequency-
distribution of receptor levels, since only 25% of rats given 
2 mg of oestradiol and exposed to 2 Gy of X-rays develop a 
malignant mammary tumour (Van Bekkum et al., 1979). The 
results in Figure 6.1 do not support an inhomogenous frequency 
distribution, and therefore it seems unlikel·y that the action 
of oestrogens on mammary tumour development is mediated 
through a specific increase in the oestrogen receptor content 
of cells that will ultimately develop into a tumour. 
Summarizing the considerations given in this section, it 
appears, that the development of mammary tumours in female 
rats exposed to exogenous oestradiol, is preceded by a pro-
longed decrease in the content of nuclear oestrogen receptors 
in the mammary tissue. This decrease, in combination with a 
possible interference in receptor replenishment and/or de 
~ receptor synthesis, is suggested to result in a decreased 
sensitivity to oestradiol of the mammary tissue. It remains 
to be investigated whether a decreased sensitivity to oestro-
gens plays a role in the growth of mammary tumours. 
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iE_£~~-EE~~~~E-~E~~y 
The model for mammary carcinogenesis described in the 
present study is based on the observation that oestrogens 
and ionizing radiation can act synergistically to increase 
the occurrence of mammary tumours in female rats (Segaloff & 
Maxfield, 1971; Shellabarger et al., 1976; Broerse et al., 
1978). While our experiments were in progress, it appeared 
that this synergism was not observed in all rat strains. 
Moreover, the amount of oestrogen implanted appeared to be 
important (Holtzman et al., 1979). In Table 7.1 the present 
knowledge about the simultaneous action of oestrogens and 
radiation in rat mammary carcinogenesis is summarized. The 
data in this table show, that, in at least three rat strains 
(AxC, Wistar and Sprague-Dawley), the action of oestrogen 
and radiation is accompanied also by an increase in the 
plasma prolactin concentration and the development of pitui-
tary tumours. In the Sprague-Dawley substrain studied by 
Shellabarger et al. (1978), no cocarcinogenic effect of DES 
was observed, whereas the rise in plasma prolactin concentra-
tion was ''only'' 5-fold and no pituitary tumours were observed. 
Since no cocarcinogenic effect of DES was observed, it is 
tempting to speculate from this observation, that only a 
large increase in plasma prolactin concentration as a result 
of oestrogen administration would be effective as cocarcino-
genic stimulus. The published data do not permit a firm con-
clusion about this aspect, since the observation period in 
these experiments was rather short (214 days). It would be 
of interest to estimate also in this Sprague-Dawley substrain 
the oestrogen receptor content of the mammary gland after DES 
implantation. If implantation of DES in female Sprague-Dawley 
rats of the substrain used by Shellabarger et al. (1978) 
would not cause a decrease of the mammary gland oestrogen 
receptor content, the involvement in carcinogenesis oE the 
decrease in the receptor content observed in the present 
67 
~ Table 7. I. 
Interaction of oestrogens and radiation in rat mammary carcinogenesis 
Rat Strain 
A X c 
A X c 
S.D. 
S.D. 
Hi star 
(liAG/Rij) 
F 344 
Type of 
radiation 
X-rays 
neutrons 
neutrons 
neutrons 
X-rays 
neutrons 
X-rays 
X-rays 
Abbreviations used: 
DES: diethylstilboestrol; 
Amount and 
quality of 
implanted 
oestrogen 
5 mg DES 
5 mg DES 
5 mg DES 
2 mg E2 
2 mg E2 
0.98 rng DES 
1.6 mg DES 
2.6 mg DES 
3.9 mg DES 
Synergism 
observed 
yes 
yes 
no 
yes 
yes 
no 
no 
yes 
no 
Rise in 
plasma 
prolactin 
n.r. 
30x 
5x 
25x 
25x 
n.r. 
E2 : oestradiol; S.D.: Spr ague-Dat..rley; 
Pituitary 
tumour 
development 
n.r. 
yes 
no 
yes 
yes 
n. r. 
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Stone et al., 1979 
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Stone et al., 1979 
Van Bekkum et al., 1979 
This Thesis, Chapter 6 
Van Bekkum et al., 1979 
Blankenstein, unpublished 
Holtzman et al., 1979 
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study (Chapter 6) would become more likely. A disadvantage 
of such a study, however, would be that the effect of implan-
tation of DES does not necessarily have to be similar to the 
observed effect of oestradiol. An alternative could be a 
study on the effect of oestradiol on the mammary gland 
oestrogen receptor content in prolactin-deprived rats of our 
Sprague-Dawley strain. 
A practical disadvantage related to both studies sug-
gested above is the long latency period (over 12 months) 
between the exposure of the rats to the carcinogenic stimuli 
and the manifestation of mammary tumours. Furthermore, large 
groups of animals are required, since not all rats will 
develop mammary carcinoma. This disadvantage might be circum-
vented by the use of DMBA, rather than radiation, as a pri-
mary carcinogen. Administration of DMBA to female rats of 
the proper strain will result in the development of more mam-
mary tumours in a relatively short time (2-3 months, Chapter 
3). With respect to the latency period and to tumour incid-
ence, the DMBA model system might, however, be less similar 
to human mammary cancer than the radiation model. 
In summary, it appears necessary tc investigate the pos-
sible involvement of a decrease in the mammary gland oestro-
gen receptor content in rat mammary tumour development with 
the aid of the radiation model in prolactin-deprived rats of 
the Sprague-Dawley strain used in the present study. 
7.3. ~~!E~E~l~!i£~_£!_~~!~-£~!~i~~~-i~-E~E-~e~~~-2Y2!~~2_!e 
~~~~~-~~~~~Ez_s!~~~-£~E£i~eg~~~~1~ 
Since the human mammary gland is relatively unaccessible 
to experimental study of carcinogenesis, it is important to 
use suitable animal model systems. For a proper extrapolation 
of data obtained in such model systems to the human situation, 
a high degree of similarity between the model and human 
tumours is a prerequisite. A number of factors which enhance 
the risk for breast cancer has been recognized from epidemic-
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logic studies. Some of these risk factors have parallels in 
rat mammary tumour models, e.g. ionizing radiation (Van 
Bekkum et al., 1979; Land & McGregor, 1979), dietary fat in-
take (Carrol, 1975; Chan et al., 1977; Cave et al., 1979; 
Hopkins & Carrol, 1979). A possible similar role for prolactin 
in the development of human mammary cancer is less clear. 
Based on the important role which prolactin could play in 
rodent carcinogenesis, Boot (1970) stressed the need for an 
extensive analysis of the relationship between human prolactin 
and breast cancer. This analysis became possible with the 
development of a radioimmunoassay for human prolactin (e.g. 
Kwa et al., 1973), but a specific role for prolactin in human 
breast cancer has not been found yet (Franz, 1978; Nagasawa, 
1979). Kwa et al. (1974) found no differences in plasma pro-
lactin levels between breast cancer patients and control 
women, but Cole et al. (1977) reported significant differences 
at certain stages of the oestrus cycle (e.g. on the fifth day 
preceding the midcycle oestradiol peak, during the follicular 
and preovulatory phases and among the highest midcycle 
levels). Recently, Kwa et al. (1978) and Tarquini et al. 
(1978) reported an abnormal rise in plasma prolactin concen-
tration in the early evening in nulliparous and obese women 
as well as in nulliparous women with benign or malignant 
breast disease. Malarkey et al. (1977) reported a change in 
the nocturnal variation of plasma prolactin in women with 
breast cancer. These results suggest that prolactin could 
play a very subtle role in human mammary carcinogenesis. 
In men, as in rodents, prolactin secretion appears to 
be stimulated by oestrogens (Frantz et al., 1972; Yen et al., 
1974; Adu-Fadil et al., 1976; Dericks-Tan & Taubert, 1976; 
Jones et al., 1977). Lind et al. (1978), however, did not 
observe a significant change in plasma prolactin levels 
during postmenopausal oestrogen replacement therapy, although 
the amounts of oestrogen administered were sufficient to 
cause decreased lutropin and follitropin levels in peripheral 
plasma. On the other hand, symptoms of amenorrhoea and galac-
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torrhoea concomitant with hyperprolactinaemia have been asso-
ciated with the use of oral contraceptive agents (Fossati et 
al., 1976; Healy et al., 1977; Tallis, 1977). 
It has also been suggested that the occurrence of pro-
lactin-secreting pituitary tumours is related to the use of 
oral contraceptive preparations (Sherman et al., 1978). 
Annegers et al. (1978) reported an increase in the incidence 
rate of pituitary adenomas in 15-44 years old women in 
Olmsted County, Minesota. Since this increase was not 
observed in males, the use of oral contraceptives was con-
sidered as a possible etiologic factor, but no significant 
association was found. Therefore it was suggested that the 
increase in the observed incidence rate of pituitary adenomas 
might be due to improved diagnostic methods (Annegers et al., 
1978; Shearman et al., 1978). 
It is tempting to speculate that the pituitary tumours 
observed in the experiments described in this thesis (Appen-
dix Papers I and III) are comparable to the prolactinomas ob-
served in human females. The symptoms associated with the 
occurrence of these tumours in rats, i.e. infertility, secre-
tory activity of the mammary gland and hyperprolactinaemia, 
are quite comparable to those seen in women. If prolactin is 
indeed capable of acting as a promotor of mammary tumour 
growth in women, the increase in the occurrence of pituitary 
adenomas should lead to an increase in the incidence of mam-
mary carcinoma. Such an increase has not been reported yet, 
but the study of this possibility certainly deserves greater 
attention. 
For the time being, it remains important to unravel the 
mechanism of mammary carcinogenesis in animal models as far 
as possible, and to identify the role of environmental 
factors known to be related to the disease. A better under-
standing of animal carcinogenesis would certainly offer a 
better model for comparison with the human situation. 
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SUMMARY 
Oestrogens and ionizing radiation can act synergistically 
in the development of mammary carcinoma in female rats. It is 
still unknown how oestrogens influence the development of 
radiation-induced tumours. It is well known, that prolactin 
can promote the growth of rat mammary tumours, and one 
possibility to explain the effect of oestrogens is through 
an oestrogen-mediated increase of prolactin in the plasma. 
Alternatively, it could be possible, that oestrogens affect 
the synthesis or the availability of their own receptors in 
mammary tissue, thus influencing the sensitivity of mammary 
tissue to oestrogens. 
It was the aim of the study described in this thesis to 
detect possible changes in the oestrogen receptor content of 
the mammary tissue and the prolactin concentration in the 
plasma of rats exposed to low doses of exogenous oestrogen 
and/or radiation (Chapter 1). If such changes would occur 
before the manifestation of mammary tumours, they might be 
related to the induction or the development of the tumours. 
Such conditions could also occur in the human through the 
widespread use of oestrogen-containing oral contraceptives 
and the increase in environmental radiation. 
The method which had to be developed for the administra-
tion to female rats of a depot of oestradiol with a sustained 
release of the hormone, has been the subject of the first 
part of Chapter 3 and Appendix Paper I. It was concluded, 
that a satisfactory small increase of oestradiol in periphe-
ral plasma can be obtained after admiriistration of the oestra-
diol by subcutaneous implantation of a pellet prepared by 
melting a mixture of oestradiol, cholesterol and paraffin. 
The exact procedure used in the present study for the prepa-
ration of these pellets and other techniques, including 
methods for the estimation of prolactin in plasma and the 
DNA content of mammary tissue preparations, are described in 
Chapter 4. 
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For a reliable evaluation of the content of oestrogen 
receptors in tissues obtained from intact animals treated 
with exogenous oestrogen, a receptor assay was developed 
which is not influenced by the occupancy of receptors by 
endogenous or exogenous oestrogen. This assay, which uses 
exchange of receptor-bound oestradiol with radioactive ligand 
in nuclear preparations of mammary tissue, is presented in 
Chapter 5 and Appendix Paper II. To evaluate this assay, it 
was necessary to use a tissue which is similar to mammary 
gland tissue and which is known to contain oestrogen 
receptors. For this purpose we used mammary tumours induced 
in female rats by oral administration of dimethylbenzenthra-
cene as described in the second part of Chapter 3. 
The main experiment in the present study is described in 
Chapter 6 and Appendix Paper III. In this experiment, rats of 
the Sprague-Dawley strain were divided among four groups, and 
were given either no treatment, oestradiol treatment, radia-
tion treatment, or oestradiol treatment followed by radiation 
treatment. The amounts of oestradiol implanted (2 mg) and the 
dose of X-rays delivered (2 Gy) were known to result within 
14 months in the development of mammary tumours in about SO% 
of the rats. In addition, these treatments are known to act 
synergistically in the occurrence of malignant mammary 
tumours. With intervals of 2 months, the oestrogen receptor 
content of the mammary tissue and the prolactin concentration 
in the plasma were estimated in 6 rats of each group for a 
period of 14 months. The following results were obtained: 
1. Oestradiol treatment caused a prolonged reduction of the 
estimated number of oestrogen receptors in the mammary 
gland, in spite of the continuous presence of oestradiol, 
which was expected to stimulate oestrogen receptor synthe-
sis. 
2. Oestradiol treatment caused a prolonged increase in the 
prolactin concentration in peripheral plasma. 
3. The oestrus cycle disappeared in animals treated with 
oestradiol. 
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4. Radiation had no effect on the parameters studied, in spite 
of the reported synergistic interaction with oestradiol 
treatment on the occurrence of malignant mammary tumours. 
5. The changes caused by oestradiol treatment in the oestrogen 
receptor content of the mammary tissue, as well as in the 
plasma prolactin concentration and the oestrus cycle, were 
already present at 2 months after treatment, which is well 
before the time that mammary tumours become manifest (10-
12 months after treatment). 
From these results it cannot be concluded whether the effect 
of oestrogens on mammary tumour development is related to one 
or more of the changes observed. Further investigations will 
have to determine, whether and which, if any, of these changes 
are involved in rat mammary carcinogenesis. 
Finally, in Chapter 7, the possible role of oestrogen re-
ceptors in mammary tumour development is discussed, the expe-
rimental model for mammary carcinogenesis used in this study 
is evaluated, and brief reference is made to a possible extra-
polation of data obtained in experimental models to human mam-
mary cancer. It is emphasized, that it is important to unravel 
the mechanism of mammary carcinogenesis in rodents, since a 
better understanding of animal carcinogenesis will certainly 
offer a better model for comparison with the human situation. 
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SAMENVATTING 
Wanneer ratten die met oestrogenen behandeld zijn~ worden 
blootgesteld aan neutronen- of rOntgenstraling, ontwikkelen 
zich meer maligne mammatumoren dan op grand van de afzonder-
lijke effekten van oestrogenen en straling verwacht zou 
worden. Deze zogenaamde synergistische werking van oestro-
genen en straling is beschreven voor de oestrogenen diethyl-
stilboestrol en oestradiol, en diverse doses hoog- en laag-
energetische neutronenstraling en rOntgenstraling~ De manier 
waarop oestrogenen het ontstaan of de ontwikkeling van mamma-
tumoren bij de rat beinvloeden, is niet bekend. Uit de lite-
ratuur was bekend, dat toediening van oestrogenen aan ratten 
de afgifte van prolaktine door de hypofyse kan stimuleren, 
terwijl prolaktine de groei van mammatumoren in knaagdieren 
kan stimuleren. Op grond van deze gegevens is overwogen, of 
het waargenomen synergisme tussen oestrogenen en straling 
zou kunnen berusten op een stijging van de prolaktinekoncen-
tratie in bet plasma, waardoor de groei van mammatumoren 
wordt gestimuleerd. Anderzijds kan echter een direkt effekt 
van de oestrogenen op bet melkklierweefsel niet bij voorbaat 
worden uitgesloten door de aanwezigheid van receptoren voor 
oestrogenen in bet melkklierweefsel. 
Volgens bet algemeen aanvaarde werkingsmechanisme van 
steroidhormonen, oefent oestradiol zijn werking op doelwit-
weefsels uit door middel van binding aan cytoplasmatiscbe 
eiwitten met een boge bindings-affiniteit voor bet bormoon. 
Deze eiwitten, ''receptoren'' genaamd, binden bet bormoon, 
zodra dit de doelwitcel binnengaat. Ret ontstane bormoon-
receptorkomplex begeeft zicb van bet cytoplasma naar de eel-
kern, waar bet gebonden wordt aan acceptorplaat~n op bet 
cbromatine. Hier stimuleert bet komplex de syntbese van mRNA, 
betgeen uiteindelijk leidt tot bet waargenomen effekt van 
het bormoon op de doelwitcel. Op deze wijze kunnen oestroge-
nen de groei van het weefsel, of de syntbese van bepaalde 
eiwitten stimuleren. Een van de effekten van oestradiol zou 
de stimulering van de synthese van de eigen receptor kunnen 
zijn. Door beinvloeding van 0£ bet aantal, Of de beschikbaar-
heid van de oestrogeenreceptoren, zouden oestrogenen hun 
eigen effekten op bet melkklierweefsel kunnen beinvloeden. 
De in dit proefschrift beschreven experimenten werden 
uitgevoerd met bet doel om mogelijke veranderingen in bet 
gehalte aan oestrogeenreceptoren van bet melkklierweefsel en 
in de prolaktinekoncentratie van bet plasma aan te tonen in 
ratten die behandeld werden met oestrogenen en al dan niet 
bestraald werden (Hoofdstuk I). Wanneer deze veranderingen 
vooraf zouden gaan aan bet manifest worden van mammatumoren, 
dan zouden zij een rol kunnen spelen bij bet ontstaan of de 
ontwikkeling van de tumoren. Ret werkingsmechanisme van 
steroidhormonen, de hormonale invloeden op normaal en neo-
plastisch melkklierweefsel en bet belang van de aanwezigheid 
van oestrogeenreceptoren in mammatumoren zijn beschreven in 
Roofdstuk 2. 
De methode die gebruikt is om een continue, geringe ver-
hoging van de oestradiolconcentratie in plasma te verkrijgen 
is beschreven in bet eerste deel van Roofdstuk 3 en Appendix 
Paper I. Implantatie van een oestradiol-bevattend tablet op 
cholesterol- en paraffinebasis gaf de beste resultaten. De 
tabletten werden bereid door een homogene smelt van de drie 
stoffen af te laten koelen in een siliconenrubberslang, en 
deze vervolgens in plakjes van 3 mm dikte te snijden. Ret 
protocol voor de bereiding van de tabletten en de methoden 
gebruikt voor de bepaling van prolaktine in plasma en DNA in 
kernen van melkklierweefsel, zijn beschreven in Roofdstuk 4. 
Bepaling van bet gehalte aan oestrogeenreceptoren in 
een weefselmonster geschiedt in het algemeen door de bepaling 
van de hoeveelheid radioaktief oestradiol die aan de recep-
toren gebonden kan worden. In weefsels afkomstig van met 
oestradiol behandelde, intakte dieren zou een dergelijke be-
paling echter beinvloed worden door bezetting van de recep-
toren door endogeen of exogeen oestradiol. Rierdoor zouden 
slechts de niet-bezette receptoren radioaktief oestradiol 
79 
binden, zodat het totaal aantal aanwezige receptoren wordt 
onderschat. Daarom werd een methode voor de bepaling van het 
totaal aantal (bezette en onbezette) receptoren ontwikkeld, 
welke niet gestoord wordt door de aanwezigheid van niet-
radioaktief oestradiol. Bij deze methode, beschreven in 
Hoofdstuk 5 en Appendix Paper II, wordt het eventueel aan-
wezige niet-radioaktieve oestradiol uitgewisseld tegen radio-
aktief oestradiol. Veer de evaluatie van de toepasbaarheid 
van deze bepaling werd gebruik gemaakt van mammatumoren welke 
ontstaan in vrouwelijke ratten na toediening van dimethylben-
zanthraceen, zeals beschreven in het tweede deel van Hoofd-
stuk 3. 
Ret belangrijkste experiment uit deze studie is beschre-
ven in Hoofdstuk 6 en Appendix Paper III. Sprague-Dawley 
ratten werden behandeld met oestradiol, met rOntgenstraling~ 
of met oestradiol en bestraling. Ratten uit een kontrOlegroep 
werden niet behandeld. De geimplanteerde hoeveelheid oestra-
diol (2 mg) en de dosis toegediende straling (2 Gy) werden 
zodanig gekozen, dat binnen 14 maanden ontwikkeling van 
mammatumoren bij ongeveer 50% van de ratten te verwachten 
was. Bovendien was bekend, dat deze behandelingen een syner-
gistisch effekt hebben op het ontstaan van maligne mamma-
tumoren. Met tussenpozen van 2 maanden werden in 6 ratten van 
elke groep het gehalte aan oestrogeenreceptoren in het melk-
klierweefsel en de koncentratie van prolaktine in het plasma 
bepaald. De volgende resultaten werden verkregen: 
1) Na behandeling met oestradiol was het gehalte van oestro-
geenreceptoren in melkklierweefsel langdurig verlaagd, in 
tegenstelling tot de verhoging welke verwacht werd op 
grond van de voortdurende aanwezigheid van oestradiol. 
2) De prolaktinekoncentratie in het plasma van dezelfde 
dieren was langdurig (10-50 x) hoger dan het prolaktine-
gehalte in plasma van dieren uit de kontrOlegroep. 
3) Dieren die met oestradiol behandeld waren, vertoonden 
geen oestruscyclus meer. 
4) Bestraling had geen additioneel effekt op de bestudeerde 
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parameters, ondanks de synergistische werking met oestra-
diol op bet ontstaan van maligne mammatumoren. 
5) De onder I t/m 3 genoemde veranderingen manifesteerden 
zich reeds 2 maanden na bet implanteren van het oestra-
dioltablet. Dit tijdstip ligt ver veer het tijdstip waar-
op de eerste mammatumoren worden waargenomen (10-12 
maanden na bebandeling). 
Op grond van deze resultaten lijkt bet mogelijk dat bet 
effekt van oestradiol op bet ontstaan van mammatumoren bij 
de rat gerelateerd is aan een of meer van de na 2 maanden 
reeds waargenomen veranderingen. Verder onderzoek is nodig 
om vast te kunnen stellen Of, en zo ja welke van, deze ver-
anderingen een rol spelen in de carcinogenese van de melk-
klier. 
De algemene diskussie in Hoofdstuk 7 betreft o.a. de 
rol die oestrogeenreceptoren zouden kunnen spelen bij de 
ontwikkeling van mammatumoren bij de rat. Tevens is gepro-
beerd bet in deze studie gebruikte model te evalueren en ten-
slotte werd aandacht besteed aan extrapolatie van gegevens 
uit dier-experimentele studies naar de situatie bij de mens. 
Ret blijft belangrijk om met behulp van diermodellen een zo 
volledig mogelijk inzicht te krijgen in alle faktoren en 
processen die leiden tot het ontstaan van mammatumoren. Op-
heldering van het mechanisme van de carcinogenese in dier-
modellen zal ongetwijfeld een leidraad bieden veer de ophel-
dering ~an bet mechanisme van de carcinogenese bij de mens. 
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LIST OF ABBREVIATIONS 
DES 
DMBA 
DNA 
EE 
ER 
M 
n 
NRS 
PBS 
r 
RNA 
s 
S.d. 
s. e.m. 
SHBG 
w/v 
w/w 
x-rays 
- bovine serum albumin 
- degrees Celsius 
- diethylstilboestrol 
- 7,12-dimethyl-benzanthracene 
- deoxyribonucleic acid 
- l7a-ethinyloestradiol 
- oestrogen receptor 
- relative centrifugal force 
- tritium 
- dissociation constant 
- messenger RNA 
- moles per litre 
- number of observations 
- normal rabbit serum 
- phosphate buffered saline 
- correlation coefficient 
- ribonucleic acid 
- Svedberg unit 
- standard deviation 
- standard error of the mean 
- sex hormone binding globulin 
- weight/volume 
- weight/weight 
- ROntgen rays 
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LIST OF TRIVIAL NAMES 
Trivial name used in this 
thesis 
aldosterone 
cholesterol 
diethylstilboestrol 
17~-ethinyloestradiol 
oestradiol 
oestrone 
progesterone 
testosterone 
Systematic name 
- 4-pregnen-118,21-diol-3,18,20-
trione 
- 5-cholesten-38-ol 
- 3,4-bis(4-hydroxyphenyl)-3-
hexene 
- I7a-ethinyl-1,3,5(10)-oestra-
triene-3,I7S-diol 
- l,3,5(10)-oestratriene-3,17S-
diol 
- 3-hydroxy-1,3,5(10)-estra-
triene-17-one 
- 4-pregnene-3,20-dione 
- 178-hydroxy-4-androsten-3-one 
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The Effect of Subcutaneous 
Administration of Oestrogens on 
Plasma Oestrogen Levels and Tumour 
Incidence in Female Rats* 
M.A. BLA!'\KE!'\STEI~.tt J. J. BROERSE,§J. B. de VRIES,§ K. J. VAN DEN BERG,§ 
S. KNAAN§ and H. J. VAN DER MOLENt 
t Departmmlt!} Bindl<7nistl)' (Dh•ision of Chemical Endocrinolo,r.y), Medical F(UU.lty, 
Erasmus University Rotterdam, Rotterdam, Tire Netlv:rla:nds, and 
§Radiobiological Institute TNO, !51 Lange Kleiweg, Rijswijk, Tire Netherlands 
Abstract-A study rm a pw.sible ,ynagislic 1j)at oj oeo'lrogmJ and ioni::.ing radiation on 
mammary carcinogerusis required the use of female rats with ef,·~·attd plasma levels of 
oestrogens in a longitudinal experiment. Follmcing suhcutalltous implantation of oeJtro,!Zcn 
pellets, plasma oestrogen levels wert monitored as a function of time after administration, 
procedure of pdlet preparation. clu:mical nature of tlu oestrogen and concmtration of tht 
oestrogen in tht pellets. 1 7 (J-oestradiof (£;:). 17 (J-or!>trodiol 3-bm::.oa/t· (E2B) and 17:x-
ethyny{o,•stradiol (E£2 ) wne studied in this respect. In initial studies, 5-20 mg E2B were 
implanted.: this resulted in extremely high peripheral plasma l<'lxLJ and cauud dtterioration 
in the phy,icol condition of the animalj. Afta a latent paiod of! 0-12 months, pituitary and 
mammary tumours were observed in a considerable number of animals. 
Experiments with petlets containing tritium labelled 17 {J-ot.strodiol were performed in 
order to compare the kir1e1ics of hormone rdeosefrom pell<'l ... l produud by ~arious techniques. 
Based on the re;;ults of these experiments, implantation of oestrogen in a paraffin-cholesterol 
pelh·t was adopted for atljurt!ur experiments. Peripheral pla.1ma le~ds ofocstro,(!m are 
reported for 17 {J-oestradiol and l7:x-ethynylocs/radiol at various time intcrJals after 
administration of ptlltts containin,IZ 1.0 a:nd 2.5 mg of oestrogen to intact and ovariectomi;.ed 
rots. 
INTRODUCTION 
IN VIEW of the relatively high incidence of 
mammary cancer in the human, it is of great 
importance to unravel the mechanism of mam· 
mary gland carcinogenesis in experimental 
models. Previous studies have suggested a 
relationship between the occurrence of mam-
mary tumours in the human and several factors, 
including radiation [I], nutritional status [2] 
and oestrogen use [3, 4]. Furthermore, it has 
been shown [5, 6] that, in the rat, oestrogen 
(diethylstilboestrol, DES) and ionizing radiation 
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(X-rays and neutrons) act synergistically to 
produce mammary tumours. In these studies, 
DES was administered to female Ax C rats via 
subcutaneous implantation of hand pressed 
DES-cholesterol pellets containing 5 mg DES 
and 15 mg cholesterol. However, the authors 
provided no data on the actual levels of DES in 
peripheral plasma after implantation. For a 
proper evaluation of the possible carcinogenic 
effect of the administered oestrogen, it is 
important to know the relationship of the 
oestrogen plasma level after oestrogen adminis-
tration to the physiological oestrogen level. 
The present study was designed to define the 
hormonal status of expenmental animals during 
combined oestrogen and radiation treatment in 
tenns of oestrogen levels in peripheral plasma, 
rather than in terms of the amount of oestrogen 
implanted in the animal. In this respect we have 
studied l i ,8-oestradiol (E2 ), 1 7 ,B..oestradiol-3-
benzoate (E2B) and 17ct-ethynyloestradiol 
I-1 
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(EE~ ). since these arc eithcr naturally occurring. 
therapeutic or contra·cepti\:e oe~trog:cns. 
MATERIAL AND METHODS 
Animals 
Female \Yistar \VAG/Rij rats either intact or 
after hy.stero~ovariectomy (Ovex) were used 
throughout this study. The animab wen' kept in 
rooms with controlled temperature. light and 
humidity conditions ::md recciwd tap water and 
standard dr;.· pellets ad libitum. Oe.strog:cn pelkts 
were implanted subcutan(•ously in tht• dor~al 
region of the neck under light ether :macsthesia. 
Blood was taken from the tail under light ether 
anaesthesia at regular intervals alief pellet 
implantation. The blood was collected in hep-
arinized tubes and centrifuged within :? hr tn 
obtain plasma, this was stored at- 20 C until 
assay. 
Preparation of otstrogm pdlt"IS 
Oestrogen pellets were prepared by one oftlw 
following methods: 
).1ethod A 
The oestrogen was mixed with an appropriate 
amount of cholesterol. The mixtur(" was pre~sed 
with a small hand~opcrated press to giw pcllcb 
weighing 21.8 ± 2.3 rug (mean± S.D .• n = 109) 
with a cross section of approximately 4 mm. 
Method B 
The oestrogen was mixed with cholesterol. 
The mixture was melted in an oil hath at l90'C 
and was aspirated into silicon tubing of 3 mm 
cross section in 0.5 ml portions .. \lier c-oolin,e; the 
tube at ambient temperature. se,!.';nWnb ol':? :.; 
mm were cut. 
:'victhod C 
A mixture of oestrogen. chok~h·rol and 
paraffin was made and pdkts were preparecl ;1~ 
described !Or method B. Chok""Sterol and para1lin 
were used in a I : 10 (w/w) ratio [7]. Tlw a\-crage 
pellet weight was 20.3 ± 1.3 mg (S.D .. n = I 00 ). 
Pellets selected for implantation weighed 19-
21m~. Tritiated oe~trogen~ were included in the 
pellets in some experi~ent~ and ~tcroid reka~e 
was monitored by liquid scintillation counting- of 
small blood sample; t:tkcn at regular intcrYab 
after pellet implantation. In a counting vial. 0:2 
ml of heparinized blood, 0.2 ml of boprop~ I 
alcohol and 0.2 ml of a 30''" solution ofhydrogen 
peroxide were mixe-d and incubated at 60 C l"or 
1 hr to decolorize the blood. The re~iduc wa~ 
dissolved after incubation with 2 ml of Solucnc 
(Packard) for another 2 hr at 60 C. Finally. I;) 
ml of Pcrmablend ~cintillation c-ocktail (Pa<"k-
ard) were added and thC" radinaC"d\·it~ \\·as 
I-2 
determined in ;1 :'>ilKk:tr Chicago Mark II liquid 
~fintillation counter with a counting dliciencv of 
:tpproximatdy 10"... ' . 
Staoids 
1 7/J~Oc~tradinl ;md 1/.x~ethmvlm""StradiollOr 
implantation wert• gifts from Org~non, Oss, The 
;.;etherlands. 17 {J-Oe~tradiol 3-benzoatc was 
purchased from Sigma, St. Louis. C .S.A. 1 7 P~ 
Oestradiol and 1 i.x~eth\·tl\'loestradiol for usc as 
standards in radioimm~n~assav were obtained 
from Stt·ra1oids. Pa\vling, )l'e~\· York, "U.S.A. 
(:2..4.6,7 ,JH )~ 17 {J-Oestr;ldiol \<:as obtained from 
the Radiochemical Centre. :\mersham. L'nitd 
Kingdom and had a spccilic acti\·ity or 85 
Ciimmok. (6. 7~"H ).J h~EthvnYlot""Stradiol with 
a specific activity of+O Ci/mr:,oie was purchased 
from :\'cw England :\'uc!ear. Frankfurt am 
;-.lain. German\·, Radioactin· S(('roids were 
purilied by papt';chromatogr~phy using;1systcm 
light pctroleum:benzene:ethanol:water, in the 
ratio of5:5: 7:3 by \'olunw. Purity ofradioactiw 
~tcroids wa~ checked every two month~. 
S/noidrstimrl/ifl/1., 
Pb~m:l 1/fi-oestradiol was :l~~ayed as pre-
\·iously desc-ribed by DeJong-, Hey and \'an der 
;\lulcn 18]. Crns~ rcanion o( 171)-oe~tradiol 
3-lwnzoall· in the l ifi~oestr~diol radio~ 
immumKtss:ty was 5"... Plasma 17.x~ 
cthynyloc~tradiol was mea~urcd e~scntially as 
described by Warren and Fotherby 19]. but the 
nwthod was adaptt'd to the protocol fOr oes~ 
tr;tdiol radioimmunoassa\'. 
E: and EE1 were not ;cparatcd by the chro~ 
matog:raphic procedure used. \Yc do not expect. 
hnwewr. that endogenous I if)-oestradiol in-
tcrkred with the assav of££, in the££, treated 
rab. because the cra"~~~reac.-ion of£, ~vith the 
CE1 antiserum was 3.5"., and becamt:it appears 
re;t~onahk to a~~unw that onlY \'l'f\' little£, was 
pre~cnt after administration ~fEE:! which will 
~uppre~s pituit;n·y lutropin secretion and m·arian 
E~ secretion. 
Scoring r!f'tumolli.' 
Animals which dc\'t·lopcd m:umn~try tumours 
were killed either when tumour size w;1~ 5-6 
em, or a~ soon :ls indicated by the physical 
condition of the anim;ds. :\utops~ \\';1~ per~ 
{ixmed on all ;mim;tl~ and tlw ocrurn·n('c of 
tumour:; W:l\ rq:;istered. Pituitary tumours were 
clas~ilied as ~udl alicr histolo~-ical examination. 
RESULTS 
In ;tn initi;d cxrwrinwnt E~H~dmkst~·rol 
JWllcb wen• prepared <lC,·urdin~ to method :\. 
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These pellets contained 5 mg E2B and IS mg 
cholesterol. From 1 to 4 pellets were implanted 
in intact and ovariectomized rats. Blood samples 
were taken at day 0, 3, 7, 14 and 30 days after 
implantation and E2 was a..-;sayed in the plasma. 
The results for the intact animals are given in 
Table 1. The results obtained ,for the ovariectO-
mized animals were essentiallv the same. The 
condition of all animals was. affected by the 
oestrog-en administration and loss of hair and a 
dccre~e in body weight were generally obser-
ved. Furthermore within a latent period ofl0-12 
months, almost all rats (92°<,} developed pitu-
itary tumours: some of the intact animal~ al~o 
developed mammary tumours. The tumour 
incidence in this group of animals i~ shown in 
Table 2; control animals were still tumour free. 
In view of the high peripheral plasma E2 b·cls 
measured after administration of E.B. which 
reflect a pharmacological rather tha-n a phys-
iological condition. it was decided to deerea~e 
the amount of oestrogen to be admini~tered tO 
the animals. Comequently, the ~econd experi-
ment was designed to compare three different 
methods of pellet preparation. Two doses ofE~ 
which were lower than the amounts ofE,B u~ed 
in the first experiment were used. The- results 
obtained are presented in Fig. l and show that 
implantation of the pressed E2-cholesterol pel-
lets (method A} tends to give higher plasma 
levels than the other two methods, especially 
during the first 40 days after implantation of the 
pellets. This observation was confirmed by the 
results of the measurements of radioactivitv in 
the blood after implantation of pellets cont;un-
ing tritiated E~; tht."Se are summarized in Table 
3. The half-life of radioactivity in the blood was 
calculated from disappearance curves of plasma 
radioactivity. The part of the curve after the 
onset of the decrease in plasma £ 2, which 
normally occurred about 4 days after implan~ 
tation, was used for this calculation. 
In a third experiment, a comparison was 
made of the oestrogen release from pellets 
prepared by method C for implantation of E2 
and EE~ in intact and ovariectomized rats. The 
results ~f this experiment are shown in Fig. 2. 
There appears to be no difference betv.;een the 
rate of release of E~ and EE2 in intact and 
ovariectOmized rats. 
DISCUSSION 
The present results show that, in the rat, an 
elevated level of plasma oestrogen can be 
effectuated and maintained by the subcutaneous 
Tab/,, 1. Plasma I 7 {1-ootradio! in inlartfnnalc rats af/a imp!anlation oJpc!lets containing 5 mg 1 7 {1-oes/radia/ 3-bm;:.aat.e 
and 15 mg cholts/erol. Rtsu/ts arr gi:•m as means± S.E..\1. (n). For n = '2 indit•idual mulls are givm. All results arcexprrsscd 
a.1pg/ml 
Timeaiier I i~-oc:.tr.:tdiol (pg/ml) 
implantation number of pellet-~ impl:mted 
(day,) 2 4 
0 56± 12 (j) 
3 29= 3 131 650- 1000 1160-2250 1438 = 238 (3) 3720-2080 
44-69 389 ± 74 (31 882 ± 32 (3) 973 ± 90 (3) 1162± 190 (3) 
14 103 ± 14 (5) 484± 38 (4· l 639 = 63 (5) 1088 ± J3i (5) 1292 ± 133 (5) 
30 i1 = 
' 
(6) 285± 18 (4) 404± 48 151 841 ± 97 (51 1032 ± 190 (6) 
Table 2. Tumour inridrnu in iniaC! and omriectumi::.~d ra/s ofta implan/ntion of 1 i {J-oeslradiol3-bm::.oalf (E=B) pellets 
Number of 
pellet' 
impbnted 
4 
T ota1 amoum of 
E,B imp1:,nted 
(mgl 
5 
\0 
15 
2Ll 
*3 Multipk. 1 ,ingk tumour ''lN'r\'t'd. 
tSingk tumou~ obM'!'\'ed 0nl\, 
Total 
number of 
animab 
mtact 
ovex 
intact 5 
0\'CX 4 
iman 4 
on·:-. 
intact 5 
on·x 
Latent :'-<umber of Rat.' with 
period pituitary mammary 
(month,) tumou~ tumours 
10 5 4" 
10 4 
10 5 21 
12 3 
II 4 
10-J 1 4 
B-10 4 lj 
Ill 5 
I-3 
93 
96 
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considerations •. it is quite possible that. the 
carcinogenic effect of oestrogens on the mam-
mary gland reported by Segaloff and Maxfield 
[5]; Shellaberger et al. [6] and found in the 
present study, is an oestrogen mediated prolactin 
effect rather than a direct effect. 
reported that progesterone may protect the 
mammary gland from becoming neoplastic [22]. 
Experiments with larger groups of animals are in 
progress to confirm our observations on the effect 
of ovariectomy on mammary tumour develop-
ment and to study the role- of prolactin and 
progesterone in this respect. The occurrence of mammary tumours in 
intact rats and the absence of such tumours in 
ovariectomized rats in spite of oestrogen admin-
istration could suggest the existence of another 
ovarian factor which is involved in the induction 
of mammary tumours. In mice and rats a 
synergistic action of progesterone and oestrone 
on prolactin-induced mammary tumours has 
been described [20, 21]. In contrast, others 
Aeknowledgcro.ents-The anti-cthynyl oc~tradiol serum 
for r;1dioimmunoa.s~ay wa_~ generously provided to u> by Dr. 
K. Fotherby, Hammer>mith Hospital and Royal Post-
graduate Medical School, London. England. We wi~h to 
expre:<> our gratitude to Profes..wr Dr. D. W. van Bekkum for 
,timulating di>cus.;ions and Profe!oSOr Dr. C. F. Hollander 
and Dr. j. D. Burek for histological identification of the 
tumour.-. 
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ESTIMATION OF TOTAL OESTROGEN RECEPTORS IN DMBA-INDUCED RAT 
MAMMARY TUMOURS BY EXCHANGE OF NUCLEAR BOUND LIGAND AT LOW 
TEMPERATURE; A COMPARISON WITH RAT UTERUS 
M.A. Blankenstein, M.J. Peters-Mechielsen, E. Mulder and 
H.J. van der Molen 
Department of Biochemistry (Division of Chemical Endocrino-
logy), Faculty of Medicine, Erasmus University, Rotterdam, 
The Netherlands 
SUMMARY 
A nuclear exchange assay for the estimation of oestrogen re-
ceptors in dimethylbenzanthracene (DMBA)-induced rat mammary 
tumours is described. In brief, the method consists of trans-
location of receptor sites to the nuclei with oestradiol-l7S 
CE2); isolation of Triton-washed nuclear preparations; 
exchange of ligand by incubation of nuclear pellets with 
radioactive E2 for 1 hour at 0 C and extraction of E2-receptor 
complexes with 0.4 M KCl. 
The optimum temperature for nuclear exchange appeared to be 
0 C when a l hour incubation period was used. When nuclear 
exchange incubations were carried out at temperatures of 15 C 
or higher, the steroid-receptor complex appeared to be 
unstable. This instability is not the result of trypsin-like 
proteolytic activity, nor of dissociation of the steroid-
receptor complex during the assay procedure. Exchange of Ez 
at 0 C was also demonstrated for uterine nuclear pellets. 
Quantitative aspects of the nuclear exchange assay were 
studied in ovariectomized rats. No differences were found 
between in vivo and in vitro labelling of receptor sites. 
Comparis0n ~xtractiou-or-nuclei-bound Ez with ethanol and 
extraction of steroid-receptor complexes with 0.4 M KCl 
showed that less radioactivity was extracted from the nuclear 
preparations with 0.4 M KCl. Ethanol extraction released much 
aspecifically bound Ez from the nuclear preparations. 
INTRODUCTION 
Quantitative estimation of receptors for oestradiol-178 (E 2 ) 
is generally performed by labelling receptor sites with tri-
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tiated E4. The results of such estimations may be influenced 
by the presence of unlabelled ligand, which may bind to the 
receptors, thus preventing the binding of the radioactive 
form of the ligand to the receptors. It has been shown, that 
endogenous steroid bound to nuclear receptor sites will ex-
change with exogenously added labelled steroid. This observa-
tion has been applied to estimation of nuclear receptor sites 
through labelling of nuclear receptor preparations with radio-
active ligand. Assays for steroid receptors in which this 
concept is used, are generally called ''nuclear exchange 
assays'', and such assays for E2-receptors have been reported 
for rat uterus (1-4), dimethylbenzanthracene (DMBA)-induced 
mammary tumours (4,5) and testicular tissue (6). In these 
assays either crude nuclear preparations (1,2,4,6) or prota-
mine-sulphate precipitated steroid-receptor complexes (3,5) 
are incubated with radioactive E2 . Following the exchange of 
labelled steroid, two procedures for the quantification of 
receptors have been used most frequently. In the experiments 
of Zava et al. (3), Tsai & Katzenellenbogen (4) and Nicholson 
et al. (5) excess free steroid is removed by repetitive 
washings of the nuclear preparation or the protamine sulphate 
precipitate followed by extraction of receptor-bound radio-
active E2 with ethanol. Mester & Baulieu (2) and De Boer et 
al. (6) have used extraction of steroid-receptor complexes 
from the nuclear preparation with 0.4 M KCl, followed by su-
crose gradient centrifugation to identify and quantify the 
receptors. It is generally agreed that the nuclear exchange 
of ligand should be carried out at moderately high tempera-
tures, e.g. 15-37 C, because the rate of ex~hange at tempera-
tures below 10 C is considered to be negligible. 
It was the purpose of the present study to compare different 
methods for the quantification of oestrogen receptors follow-
ing exchange of nuclear bound ligand. In this respect, sucro-
se gradient centrifugation following KCl extraction of nuclear 
Ez-receptor complexes and determination of radioactive E2 
following ethanol extraction were studied. The results show, 
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that nuclear exchange of E2 occurs even at temperatures as 
low as 0 C~ both for uterine and for DMBA-induced mammary 
tumour tissue. In addition, it will be shown, that ethanol 
extraction of nuclear-bound tritiated E2 released high 
amounts of E2 which are not specifically bound to the nuclear 
preparation. This may cause inaccurate results for receptor 
levels in tissues with low amounts of specifically bound 
steroid. 
MATERIALS AND METHODS 
Animals 
Female Sprague-Dawley rats were used in this study. They were 
housed in a light- (14 h light, 10 h darkness) and tempera-
ture- (20-22 C) controlled room and received standard dry 
pellets (Hope Farms, Woerden, The Netherlands) and tap water 
ad libitum. Mammary tumours were induced in 54-61 days old 
rats by three intragastric feedings of 10 mg dimethylbenzan-
thracene (DMBA, Fluka, Basel, Switzerland) with one week 
intervals. The first tumours appeared 5 weeks after the first 
DMBA feeding, whereas at 10 weeks tumour incidence was 100%. 
The number of tumours per rat varied from 7-15. Histologically 
80% of the tumours were classified as adenocarcinoma, 8% as 
carcinoma, 8% as sclerosing papillary cystadenoma. The remain-
der of the lesions was classified as hyperplastic nodules. 
Ovariectomy was performed 40 hours before sacrifice under 
light ether anaesthesia through lateral incisions. Animals 
were killed by decapitation. 
Methods for the estimation of nuclear oestrogen receptors 
a) ~~£l~~!-~~£~~gg~-~~~~l 
Uterine and mammary tumour tissue were collected and trimmed 
free of fat; tumour capsules were removed. Necrotic tumours 
were not used. Tissue samples (up to 1 gram) were minced with 
scissors and incubated under constant agitation in scintilla-
tion vials containing 2-3 ml of Krebs Ringer Bicarbonate 
Buffer, pH= 7.4, containing 0.2% (w/v) of glucose (KRBG). 
Incubations were carried out for 1 hour at 37 C in an atmos-
phere of 95% oxygen and 5% carbon dioxyde in the presence of 
2 x 10-8M of unlabelled E2 (Steraloids, Pawling, New York, 
U.S.A.) in order to translocate free receptors to the nuclei. 
In some experiments the potent protease inhibitor di-isopro-
pylfluorophosphate (DFP, BDH, Poole, England) was present in 
a concentration of I mM (7). After the incubation, the vials 
were placed on ice. The incubation medium was separated from 
the tissue fragments by centrifugation at 700 x g for 10 min 
at 6 C. Unless stated otherwise, all subsequent centrifuga-
tions were performed under these conditions. Tissues and 
II-3 103 
General procedures 
Protein was measured by the method of Lowry et al~ (9) using 
bovine serum albumin as a standard. For protein estimation, 
nuclear pellets were dissolved in 1 ml of I N sodium hydroxyde 
by heating for 30 minutes at 65 C. 
DNA was measured according to Giles & Myers (10). As a sedi-
mentation marker for sucrose gradient centrifugation Bovine 
Serum Albumin (4.6 S, BSA) was used. 
The BSA was centrifuged on a separate gradient and detected 
in the fractions by its adsorption at 280 nm. 
Protamine-sulphate precipitation of receptors was performed 
according to Zava et al. (3). Nuclear extracts were diluted 
to a KCl concentration of 0.08 M prior to addition of the 
protamine sulphate (Organon, Oss, The Netherlands). 
RESULTS 
Evaluation of the nuclear exchange assay 
In Figure 1 the result of a gradient centrifugation of the 
KCl extract of a DMBA-induced mammary tumour nuclear pellet 
is presented. After nuclear exchange a small 4 S-peak is 
usually present in addition to the main peak (at 5 S). For 
calculation of receptor concentrations both peaks were used. 
A comparison of the nuclear exchange assay using incubation 
of the nuclear pellet with tritiated E2 for one hour at 20 C 
(6), and the direct nuclear receptor assay (8) using tumour 
tissue obtained from an intact rat is shown in Figure 2. From 
these results it appeared that with the direct assay no 
receptors could be demonstrated, whereas with the nuclear ex-
change assay a receptor peak was clearly visible (fractions 
8-16). This observation leads to the conclusion that in the 
direct assay, in which minced tissue of intact animals is 
incubated with radioactive steroid, the ratio of the concen-
tration of endogenous and radioactive steroid is unfavourable 
at radioactive steroid concentrations known to be effective 
in ovariectomized animals. When exchange is performed on 
washed nuclear pellets from intact animals, this concentra-
tion ratio is more favourable. 
Results of nuclear exchange assays depend on the temperature 
at which the exchange reaction is carried out and we have in-
vestigated the effect of incubation temperature and incubation 
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dpm x 10- 2 
1 0 
8 
6 
4 
2 
top 
1 0 20 
fraction number 
Fig. 2 Comparison of sucrose 
gradient centrifuga-
tion patterns obtained after 
direct in vitro labelling 
o--o and nuclear exchange 
following translocation e--o 
for the assay of oestrogen 
receptors in DMBA-induced rat 
mammary tumour tissue obtain-
ed from an intact rat. 
Nuclear exchange was carried 
out for 1 hour at 20 C. 
ER 
(% of maximum) 
1 0 0 
75 
50 
25 
0 1 0 20 30 40 
temperature ( oc) 
Fig. 3 Effect of exchange 
temperature on estima-
ted oestrogen receptor levels 
(ER) in nuclear extracts of 
DMBA-induced rat mammary 
tumour. Exchange was performed 
for 30 min (o---o) or l hour 
(o---e) at different tempera-
tures. 
time on the result of the exchange assay. The results in 
Figure 3 suggest that the E2-receptor complex in nuclear pre-
parations of DMBA-induced rat mammary tumours is not stable 
at elevated temperatures. To further evaluate this suggestion, 
DMBA-induced mammary tumour tissue from ovariectomized animals 
was incubated with 3H-E 2 to translocate all receptor sites to 
the nuclei. Nuclear preparations of this tissue were kept in 
II-7 
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ER Fig. 4 Effect of di-isopro-
(% of maximum) pylfluorophosphate (DFP) and radioactive Ez in 
isolation and incubation me-
dia on the stability of the 
176-oestradiol-receptor com-
plex (ER) from DMBA-induced 
mammary tumour tissue. Tissue 
was obtained from ovariecto-
mized animals, receptors were 
labelled by incubation of the 
tissue with radioactive 176-
oestradiol. Nuclear fractions 
were kept in exchange buffer 
for 1 hour at different tem-
peratures. •--• no additions, 
o---o DFP, x---x DFP + 3H-Ez. 
I 0 0 
75 
50 
25 
0 I 0 20 30 40 
temperature (°C) 
exchange medium for 1 hour at different temperatures. In a 
parallel set of incubations di-isopropylfluorophosphate (DFP) 
was added to all media. DFP is known to inhibit trypsin-like 
proteolytic activity even at 4 C (7). In a third set of prepa-
rations radioactive E 2 was present in addition to the DFP to 
minimize dissociation of the E2-receptor complex during the 
preparation and the handling of the nuclear fraction. From 
the results of these experiments (Figure 4) it can be conclu-
ded, that the receptor-E 2 complex in nuclear preparations of 
DMBA-induced rat mammary tumours is unstable when kept for 
hour at temperatures of 15 C or hieher. This instability is 
probably not caused by trypsin-like proteolytic activity, 
since incubation with DFP showed only a minor effect at tem-
peratures above 20 C. Addition of excess radioactive E2 to 
all media to protect the steroid-receptor complex from disso-
ciation had only a limited effect at temperatures lower than 
23 c. 
For serial estimations of oestrogen receptors in mammary tu-
mours an exchange period of 1 h at 0 C was adopted4 At this 
temperature longer incubation did not increase the amount of 
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3H-E 2 bound to the receptors (data not shown). 
The nuclear exchange assay was compared to the direct in 
vitro nuclear receptor assay and the in vivo nuclear receptor 
assay. The nuclear exchange assay was performed on tumour 
tissue from intact animals. For the direct in vitro and in 
vivo assay of nuclear receptors tissue from ovariectomized 
rats was used, since these assays require the absence of 
endogenous E 2 • The data in Table l show that the results of 
the nuclear exchange assay are equivalent to those obtained 
with both the in vivo injection and the direct in vitro 
assays. 
II-9 
--- ----
Table l 
OESTROGEN RECEPTORS IN DMBA-INDUCED RAT MAMMARY 
TUMOURS MEASURED WITH DIFFERENT ASSAYS 
Assay procedure 
KCl-extractable oestrogen 
receptor sites (fmoles/mg 
nuclear extract protein) 
b. 
In vivo labelling of 
receptors by injection 
of 3H-Ez 
In vitro labelling of 
mammary tissue with 
3H-E2 
.!!:!~S!_~gi~~l~ 
Exchange with 3H-Ez in 
nuclear preparations 
of mammary tissue 
15. 
30' 
60' 
23 c 
23 c 
0 c 
44 
49 
49 
54 
49 
60 
67 
49 
44 
109 
Low temperature ligand exchange in uterine nuclear pellets 
A uterus of a DMBA-tumour bearing rat was incubated for h 
-8 
at 37 C with 10 M unlabelled E2 . Nuclei were incubated with 
tritiated E2 at either 0 C or 15 c. The results in Figure 5 
reflect that exchange of E2 from its receptor sites at low 
temperature occurs also in uterine nuclei. 
-2 d pm x 1 0 
20 
1 0 
1 0 20 
fraction number 
Fig. 5 Sucrose gradient 
analysis of nuclear 
extracts from uterine 
tissue following exchange 
for 1 hour at 0 C (o---o, 
1.7 mg protein/ml extract) 
and 1 5 C ( •---•, 2. 5 mg 
protein/ml extract). The 
uterus was taken from an 
intact rat carrying DMBA-
induced mammary tumours. 
In contrast to the results obtained for mammary tumour tissue, 
in uterine nuclei the optimum temperature for exchange during 
hour was 15 C rather than 0 C. The amounts of receptor ex-
pressed as femtomoles/mg nuclear extract protein were 145 and 
ISO for exchange at 0 C and 15 C respectively. 
Measurement of oestrogen receptors in uterine and DMBA-induced 
mammary tumour tissue using ethanol extraction of receptor-
3 bound H-Ez 
The experiments described in this section were performed with 
uterine and DMBA-induced mammary tumour tissues obtained from 
ovariectomized rats. Receptor sites were labelled either 
directly in vitro or by nuclear exchange for one hour at dif-
ferent temperatures following translocation of receptor sites 
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to the nuclei with unlabelled E2 . Following labelling of re-
ceptors excess ligand was washed away and receptor-bound 
radioactive E2 was extracted with ethanol- The results in 
Table 2 show that the amount of aspecific binding is unaccept-
ably high in all cases, except when receptors in uterine 
tissue were labelled directly in vitro. The low figures ob-
tained with mammary tumours after exchange at 37 C indicate 
that lower exchange temperatures should be used. 
DNA content of nuclear preparations after exchange 
Since some authors (3,5) have used the DNA content of their 
preparations to express the nuclear receptor content, we have 
also measured the DNA content of our preparations. The DNA/ 
protein ratio of nuclear preparations of DMBA-induced mammary 
tumours decreased when the exchange was carried out at 37 C 
(Table 3). The protein content of the pellets did not change 
with changes in incubation temperature. From Table 3 it 
appears that the DNA-content of nuclear preparations is not 
suitable for the expression of results of nuclear exchange 
assays for oestrogen receptors in this type of tissue when 
exchange is carried out at temperatures above 20 C. 
Efficiencies of KCl and ethanol extraction 
The efficiencies of ethanol and KCl extraction of tritiated 
E2 and E2-receptor complexes respectively from nuclear prepa-
rations of uterine and DMBA-induced mammary tumour tissue 
following different labelling procedures, are presented in 
Table 4. Less radioactivity was extracted with KCl following 
nuclear exchange, whereas the efficiency of ethanol extraction 
of labelJed hormone was not affected by the labelling proce-
dure. 
Evaluation of charcoal treatment of nuclear extracts 
Since charcoal can remove oestradiol from its receptor, we 
also measured receptor sites in uterine nuclear preparations 
omitting the charcoal treatment. Quantification of receptor 
sites was performed using the protamine-sulphate precipitation 
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"' Table 2 
RESULTS OF NUCLEAR EXCHANGE ASSAY OF OESTROGEN RECEPTORS USING ETHANOL EXTRACTION OF 
RECEPTOR-BOUND OESTRADIOL-17S 
Total Bound % Aspecific Specifically Bound Tissue Assay Conditions n Radioactivity Radioactivity 
(fmole/mg protein) Binding (fmole/mg protein) 
Uterus direct in vitro 6 263 + 20 1 33 + 5 174 + 12 
exchange 0 c 4 254 + 56 54 :;: 17' 109 + 19. 
20 c 3 328 + 8 57 + 20' 137 + 35 
37 c 3 285 + 13 58 + 22. 116 + 30 
Df>1BA-tumour direct in vitro 5 431 + 74 65 + 21 fl 164 + 62 
exchange 0 c 3 527 + 144 70 + 3~ 159 + 53 
6 c 3 544 + 88 72 + 7' 146 + 24 
20 c 3 604 :+: 150 76 + 16. 114 + 37 
37 c 3 314 + 12 88 + 11. 38 + 19~ 
means + s.e.m. 
H 
H 
• significantly different from direct in vitro labelling of uterus (p < 0.05) _1. 
"' ~ significantly different from direct in vitro labelling of DMBA-tumour (p < 0.05) 
H 
H 
.'., 
w 
w 
Table 3 
----
DNA/PROTEIN RATIO OF UTERINE NUCLEAR PELLETS AFTER OESTROGEN RECEPTOR ASSAY 
DNA/protein ratio 
Assay conditions 
uterus DNBA-tumour 
direct in vitro 116 + 6 ( 12) 231 + 28 (12) 
exchange § 0 c 85 + 7 (6)' 238 + 27 ( 6) 
6 c n.d. 238 + 25 (6) 
20 c 100 + 9 (6) 232 + 19 (6) 
37 c 95 + 18 (6) 82 + 13 (6)' 
exchange time: 1 hour 
~ p < 0.05 compared to corresponding direct in vitro labelling 
n.d. = not determined 
" Table 4 
EFFICIENCIES OF KCl EXTRACTION OF OESTRADIOL-l7S-RECEPTOR COMPLEXES AND ETHANOL 
EXTRACTION OF RECEPTOR-BOUND OESTRADIOL-17S FROM NUCLEAR PREPARATIONS OF RAT 
UTERINE AND DMBA-INDUCED ~~RY TUMOUR TISSUE 
KCl extraction Ethanol extraction 
Receptor assay (% radioactivity extracted) 
Uterus DMBA-tumour Uterus DMBA-turnour 
in vivo 75 ( 2) § 46 ( 2) 93 (2) 
direct in vitro 72+11 ( 4) - 88 + 4 (10) 
nuclear exchange 48 + 9 ( 6). 35 + 1 (6) 84 + 10 (15) 93 + 12 (12) 
§ means = s.e.m. (n) or means (n = 2) 
U significantly different from in vitro receptor assay 
H z 
" 
technique (3) which, in contrast to the sucrose gradient cen-
trifugation, is insensitive to the presence of excess free 
steroid. For quantitative precipitation of receptors nuclear 
extracts were diluted to a KCl concentration of 0.08 M (3). 
We compared the results obtained after sucrose gradient cen-
trifugation of 10 charcoal-treated uterine nuclear extracts 
with those after protamine sulphate precipitation of the same~ 
yet untreated, extracts for quantification of oestrogen 
receptor sites. The results of the protamine-sulphate precipi-
tation assay were 102 ~ 3% (mean~ s.e.m., n 10) of that of 
the sucrose gradient assay. Apparently under these experimen-
tal conditions charcoal does not strip oestradiol from its 
receptor. 
Interference by non-receptor proteins 
In mammary tumour tissues, a-fetoprotein ~-FP) may be present 
(11). To evaluate if aFP would interfere with the present nu-
clear exchange assay, we assayed oestrogen receptors in ute-
rine tissue with or without addition of 50% (v/w) immature 
rat plasma prior to homogenization. The plasma, which was ob-
tained from 8-days old rats, was found to contain ll nmoles 
of oestrogen binding sites/ml. The uterine oestrogen receptor 
level was not increased after addition of the serum and 
therefore we concluded that the oestrogen receptor assay as 
presented is not sensitive to the presence of a-fetoprotein 
in the tissue to be assayed. Therefore, both oestradiol and 
diethylstilboestrol can be used as competitors in this present 
assay. 
DISCUSSION 
The results of this study show that exchange of ligand from 
E2-receptors in Triton-washed nuclear preparations of rat 
uterus and DMBA-induced mammary tumours is possible even at 
temperatures as low as 0 C (Figures 3-5). The highest values 
for the number of specific oestrogen receptor sites in DMBA-
induced mammary tumours were obtained using a combination of 
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a long incubation time and a low temperature or a short incu-
bation time and an elevated temperature (Figure 3 and Table 
I). Prolonged incubation at elevated temperatures decreased 
the number of measurable receptor sites (Figure 3). This de-
crease could only in part be explained by protease activity 
or dissociation of the steroid-receptor complex during the 
procedure (Figure 4). Because of the unfavourable effect of 
a higher exchange temperature on the stability of the 
steroid-receptor complex we have adopted the incubation for 
hour at 0 C for serial estimations of oestrogen receptors 
in mammary tumour tissue. 
For DMBA-induced mammary tumour tissue results of the nuclear 
exchange assay were compared to those obtained with an in 
vivo injection assay and direct in vitro assay. In the in 
vivo injection assay, radioactive E2 is injected in an ovari-
ectomized animal, in the direct in 
an ovariectomized rat is incubated 
vitro assay 
with 10-S M 
tissue from 
3H-E in order 2 
to translocate all receptors to the nucleus. After one hour, 
tissue is isolated and E2-receptor complexes are extracted 
from a nuclear preparation. The in vivo injection assay is 
considered to give the best reflection of the true receptor 
level of a tissue, be-cause receptors are labelled in vivo in 
----
the absence of endogenous E2 . Furthermore, the handling of 
the tissue is minimal in this assay, since no incubations 
have to be carried out to obtain translocation of receptors 
to the nuclei or nuclear exchange. Results of the in vivo 
injection assay did not differ from results obtained with 
either the in vitro labelling or the nuclear exchange assay 
(Table I). Garola & McGuire (12) demonstrated that transloca-
tion of receptors from the cytoplasm to the nuclei in vivo 
----
incomplete after surgical removal of a part of the tumour. 
This is possibly due to changes in vascularization as a 
result of the operation. Therefore tissues of different 
animals of the same litter were used in the comparison pre-
sented in Table I. 
is 
It has been reported that the level of oestrogen receptor in 
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target tissues decreases after ovariectomy. However, in view 
of the large half life of oestrogen receptors (5-6 days (13, 
14)) and the relatively short period used in our experiment 
between ovariectomy and receptor assay (40 hours), the effect 
of ovariectomy on receptor levels in our experiments was con-
sidered negligible. 
The optimal conditions found in the present study for nuclear 
exchange assay of oestrogen receptors in DMBA-induced rat 
mammary tumours are in contrast to those reported in the 
literature. Tsai & Katzenellenbogen (4) used crude nuclear 
preparations of DMBA-induced mammary tumours, a 45 minutes 
exchange period at 30 C and ethanol extraction of bound 3H-E 2 
Nicholson et al. (5) added protamine sulphate to a crude nu-
clear suspension of the tumour tissue to prevent solubiliza-
tion of receptors and exchange for 2 hours at 15 C. They also 
used ethanol extraction for receptor quantification. 
The discrepancy between our results and those reported in the 
literature cannot be explained by the ethanol extraction 
(Table 2). In addition in our hands the ethanol releases an 
unacceptably high amount of aspecifically bound E2 from the 
nuclear pellets. The expression of results per DNA content of 
the pellets also does not account for this discrepancy, since 
the DNA content is not affected by incubation temperatures of 
20 Cor lower (Table 3). 
For uterine tissue optimum exchange is not achieved after 
hour incubation at 0 C (Figure 5), which is in agreement with 
earlier findings (3,6). In contrast to those findings we did 
measure an appreciable amount of exchange when we incubated 
uterine nuclear pellets at 0 C. 
Both for uterine and DMBA-induced mammary tumour tissue the 
efficiency of KCl extraction of steroid-receptor complexes 
following nuclear exchange is lower than after in vivo or in 
vitro labelling of receptor sites (Table 4). This might 
reflect a change in compartmentalization of the E2-receptor 
complex during the different incubations used in nuclear ex-
change assays. It has been suggested (15) that the tightly 
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bound receptor sites which cannot be extracted with 0.4 M KCl 
are the most important ones in the action of steroid hormones 
on the target cell. Repeated extractions with 0.6 M KCl, how-
ever, appear to release more than 90% of the steroid-receptor 
complexes from the nuclei (16,17). The extraction efficiency 
for a single KCl extraction following direct in vitro label-
ling of uterine E2 receptors reported by these authors is in 
agreement with our findings (Table 4). Although we do not 
extract all steroid-receptor sites from the nuclear prepara-
tions, the reproducibility of a one step 0.4 M KCl-extraction 
of such preparations is within acceptable limits (Table 4). 
Data from a preliminary communication by Laing et al. (18) 
suggest that for human mammary tumours incubation of crude 
nuclear pellets with radioactive E2 for 18 hours at 4 C as 
well as at 20 C and at 37 C would result in complete exchange. 
They also reported that the rat uterine receptor does not ex-
change its ligand at low temperature, which is in contrast to 
our findings (Figure 5). Kiang (19), however, suggests that 
the nuclear receptors measured at low temperature by Laing et 
all (18) would be in the free form and would not contribute 
to the hormone-dependent nature of a tumour. Garola & McGuire 
(12) demonstrated that free receptors do not occur in nuclei 
of DMBA-induced mammary tumours. 
It is generally accepted that cytoplasmic oestrogen receptors 
are activated upon binding of E2 and that the sedimentation 
coefficient of the receptor shifts from 4 S to 5 S during 
this process (20). Recently, Linkie & Siiteri (21) have pre-
sented evidence that this activation could also occur in ute-
rine nuclei within 5 min after exposure to tritiated oestra-
diol-17S. After a labelling period of one hour, however, the 
4 S component accounted for only 13% of the total amount of 
receptors. As shown in Figure l, a small 4 Speak could also 
be detected in the nuclear extract of DMBA-induced mammary 
tumours. 
Eriksson et al. (22) and Clark et al. (23) have proposed the 
presence of two types (I and II) of oestrogen receptors in 
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uterine cytosol and nuclei. It was suggested, that the type 
II cytoplasmic receptor was different from the type II nuclear 
receptor. The type I nuclear receptor, which would be the 
type I cytosol receptor translocated to the nuclei would be 
physiologically active and would not be readily labelled at 
low temperature. Notides et al. (24) and Traish et al. (25), 
however, observed only a single oestrogen receptor in uterine 
nuclear extracts, which sedimented at 5 S. No essential dif-
ferences in labelling at 0 C and 37 C were observed, but equi-
librium was reached slower at 0 C than at 37 C. Therefore it 
appears that the presence of two separate types of nuclear 
oestrogen receptors in uterine tissue is still a matter of 
debate. Furthermore, for other oestrogen target tissues, as 
the DMBA-induced rat mammary tumour used in the present study, 
there is no evidence for the possible presence of two types 
of oestrogen receptors. Since the present assay measures pre-
dominantly 5 S receptors which are considered to be the phy-
siologically active sites (20), we conclude that the nuclear 
exchange assay as described offers a reliable estimation of 
the total amount of receptors. 
In conclusion, from the present results a nuclear exchange 
assay employing a 1 hour 0 C exchange period for oestrogen 
receptor in DMBA-induced rat mammary tumours has been 
developed, which also gives good results for normal mammary 
tissue (to be published). The advantages of this assay are 
the distinct sedimentation patterns of steroid-receptor com-
plexes after sucrose-gradient centrifugation ~nd the absence 
of interference by endogenous E2 or non-receptor oestrogen 
binding proteins. 
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OESTROGEN RECEPTORS IN MAMMARY TISSUE AND PLASMA PROLACTIN 
CONCENTRATIONS DURING MAMMARY CARCINOGENESIS IN RATS INDUCED 
BY OESTROGEN AND IONIZING RADIATION 
M.A. Blankenstein, E. Mulder, J.J. Broerse* and H.J. van der 
Molen 
Department of Biochemistry (Division of Chemical Endocrino-
logy), Erasmus University, Rotterdam and xRadiobiological 
Institute TNO, Rijswijk, The Netherlands 
SUMMARY 
The amount of nuclear oestrogen receptors in mammary tissue 
and plasma concentrations of prolactin were studied in female 
rats for a period of 14 months after administration of a cho-
lesterol-paraffin pellet containing 2 mg of oestradiol, and/ 
or exposure to 2 Gy (200 rad) of X-rays. Oestrogen receptors 
were estimated after in vivo translocation of free receptors 
to the nucleus with nUClear-exchange assay at low temperature. 
Oestrogen treatment resulted in a decrease of the content of 
oestrogen receptors of the mammary tissue of both irradiated 
rats and non-irradiated rats. In oestrogen-treated rats plasma 
prolactin was elevated 10-50 times and pituitary tumours were 
observed. Radiation had no additional effect on the mammary 
tissue oestrogen receptor content and the plasma prolactin 
concentration. The changes in the oestrogen receptor content 
of the mammary tissue and the prolactin concentration of the 
plasma preceded the development of mammary tumours. The 
results obtained suggest that the effect of oestrogens in the 
synergistic interaction of oestrogens and radiation on rat 
mammary tumour development is related to the large increase 
in the plasma prolactin concentration and/or the decrease in 
the oestrogen receptor content of the mammary tissue. 
INTRODUCTION 
Oestrogens and radiation can act synergistically in the 
development of mammary tumours in female rats (Segaloff & 
Maxfield, 1971; Shellabarger, Stone & Holtzman, 1976; Broerse, 
Knaan, Van Bekkum, Nooteboom, Hollander & Van Zwieten, 1978). 
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The mechanism through which oestrogens enhance radiation-
induced mammary carcinogenesis has not been elucidated yet. 
It is, however, generally accepted, that oestrogens exert 
their effect(s) on target tissues through specific receptors 
present in the cytosol, followed by translocation of the 
oestrogen-receptor complex from the cytosol to the nucleus, 
interaction with the chromatin and induction of mRNA synthe-
sis, which ultimately leads to the observed effect of the 
hormone. One of the effects of oestrogens would be the stimu-
lation of oestrogen receptor synthesis (Sarff & Gorski, 1971; 
Mester & Baulieu, 1975). Oestrogens are also known to stimu-
late pituitary prolactin release (Chen & Meites, 1970). 
From these observations at least two mechanisms can be con-
sidered to explain the effect of oestrogens in rat mammary 
carcinogenesis. Firstly, oestrogens could influence mammary 
tissue by influencing the synthesis of their own receptorss. 
Secondly, since prolactin appears to play a major role in 
mammary tumour development in the rat (Meites, 1972), oestro-
gens could exert their cocarcinogenic action via an increase 
in the plasma prolactin concentration. 
It was the aim of the present investigation to relate the 
synergistic action of oestradiol and ionizing radiation on 
rat mammary tumour development to possible changes in the 
mammary gland oestrogen receptor content and/or the plasma 
prolactin concentration. Therefore, mammary gland oestrogen 
receptors and plasma prolactin were estimated in rats at 
different times after the administration of oestradiol and/or 
exposure to X-rays. It will be shown that during the period 
of mammary tumour development the content of oestrogen recep-
tors in the mammary gland decreased, whereas the plasma pro-
lactin concentration was greatly increased. 
MATERIALS AND METHODS 
Female Sprague-Dawley rats from the REPGO-strain were used in 
this study, because of their high susceptibility to radiation-
induced mammary carcinogenesis (Broerse et al., 1978). They 
were housed, five to a cage, on wood shavings and had free 
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access to tap water and standard laboratory chow (Hope Farms, 
Woerden, The Netherlands). Oestrogen pellets were implanted 
subcutaneously in the dorsal region of the neck at the age of 
7 weeks. Radiation was given at 8 weeks of age. The rats were 
divided among four groups, receiving either no treatment, 
oestrogen treatment, radiation treatment, or oestrogen plus 
radiation treatment. 
Cholesterol-paraffin pellets containing 2 mg of oestradiol 
were prepared essentially as described previously (Blanken-
stein, Broerse, De Vries, Van den Berg, Knaan & Van der Molen, 
1977). Cholesterol and paraffin were used in a 1:3 (w/w) 
ratio, rather than in a 1:10 (w/w) ratio, since oestradiol 
dissolved faster in a melt containing the higher amount of 
cholesterol. The oestradiol concentrations reached in peri-
pheral plasma following implantation of pellets with a 
cholesterol-paraffin ratio of 1:3 (w/w) (see: Results section) 
were not different from those observed after implantation of 
pellets with a cholesterol-paraffin ratio of 1:10 (Blanken-
stein et al., 1977). Radiation treatment was given as a single 
dose of 2 Gy (200 rad) X-rays. When given this dosage, approx-
imately 50% of the rats is expected to develop mammary tumours 
within 14 months (Broerse et al., 1978), and a synergistic 
interaction of oestradiol and radiation on mammary tumour 
development has been observed (Van Bekkum, Broerse, Van 
Zwieten, Hollander & Blankenstein, 1979). Vaginal smears were 
taken daily from a number of rats to assess the oestrus cycle 
stage. Oestradiol-treated rats showed a persistent oestrus. 
Animals which were not treated with oestradiol were used in 
the metoestrus phase of the cycle to circumvent possible fluc-
tuations of oestrogen receptor levels during the cycle. With 
intervals of two months, six animals from each group were 
killed. Before killing the animals by decapitation, the rats 
were anaesthesized with ether and a 2-3 ml blood sample was 
collected in heparinized tubes after amputation of a 2 em 
piece of the tail. Subsequently, the animals were injected 
subcutaneously with a solution of 25 ~g of oestradiol in 0.1 
ml of olive oil. This treatment resulted in an oestradiol 
concentration in the plasma of 7.5 + 1.0 ng/ml (mean+ s.e.m., 
n = 1) and should cause the transfer of all cytoplasmic 
receptors to the nuclei. One hour after the injection, the 
animals were killed by decapitation and the six inguinal mam-
mary glands were excised and placed on ice. 
Oestrogen receptors were estimated in the mammary tissue with 
the low-temperatur~ nuclear exchange assay as published else-
where (Blankenstein, Aitken-Cook, Mulder & Van der Molen, 
1978; Blankenstein, Peters-Mechielsen, Mulder & Vander Molen, 
1980). Briefly, the method consists of translocation of free 
receptors to the nuclei through the injection of 25 ~g of 
oestradiol, preparation of a Triton X-100 washed crude nuclear 
pellet, exchange of unlabelled oestradiol with to-8 M 3H-
oestradiol, extraction of 3H-oestradiol-receptor complexes 
with 0.4 M KCl, adsorption of excess free steroid to Dextran-
coated charcoal, separation of free and bound steroid by cen-
trifugation of the nuclear extract for 2 h and 45 min at 
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65,000 rpm in a Beckman VTi-65 rotor through linear 10-30% 
sucrose gradients, fractionation of the gradients and deter-
mination of radioactivity in the separate fractions. Oestrogen 
receptor values were expressed per mg of protein in the 
nuclear extract. Plasma prolactin was assayed with a homolo-
gous double antibody radioimmunoassay based on the method 
described by Kwa, Vander Gugten & Verhofstad (1969). Rabbit 
anti-rat-prolactin serum was a gift from Dr. H.G. Kwa 
(Netherlands Cancer Institute, Amsterdam). Prolactin reference 
preparation RP1 was kindly provided by Dr. A.F. Parlow (Rat 
Pituitary Hormone Distribution Program, NIAMDD, NIH, Bethesda, 
MA, U.S.A.). Commercially available 125I-rat-prolactin (New 
England Nuclear, Dreieich, Germany) with a specific activity 
of 1500 +50 kBq/~g (42.1 + 1.4 ~Ci/~g) was used as a tracer. 
Donkey aUti-rabbit serum (Wellcome, Beckenham, England) was 
used as precipitating serum. Plasma oestradiol concentrations 
were measured according to De Jong, Hey & Van der Molen 
(1973). 
RESULTS 
Macroscopic observations 
The increase in body weight of oestradiol-treated rats was 
much slower than that of animals receiving no oestrogen 
(Table 1). Since radiation had no effect on the growth, the 
data from the groups not receiving oestradiol were pooled and 
Table I. Body weight of rats treated with oestradiol and rats 
given no oestrogen treatment at different intervals 
after the start of the experiment. Results are means + s.e.m. 
( n) . 
Time after Body weight (g) 
treatment 
(months) oestrogen no oestrogen 
2 173 + 3 (8)" 208 + 6 ( 6) 
4 201 + 7 (13)" 237 + 6 (I 0) 
6 208 + 7 (8)" 239 + 5 (9) 
8 213 + 14 (5)" 241 + 5 ( I I ) 
I 0 230 + 6 (IS)" 255 + 6 (8) 
12 254 + I 2 (I 2) 255 + 8 ( I I ) 
14 278 + 18 (8) 272 + 13 (9) 
*p < 0. 05 vs. no oestrogen (Student's t-test) 
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compared with the pooled data from the two oestradiol-treated 
groups. A significant difference in body weight between the 
two groups was observed up to 10 months after the start of 
the experiment. In addition~ oestradiol treatment caused the 
disappearance of the oestrus cycle and a massive stimulation 
of the mammary glands with the formation of large secretory 
vesicles. From 10 months after oestrogen treatment, pituitary 
tumours were found at autopsy in more than 50% of the animals. 
Irradiated rats showed pin point red dots all over the mam-
mary tissue during the first 8 months after irradiation. Fur-
thermore, at two months after irradiation small nodules were 
observed in the mammary glands of three rats out of five rats 
which were examined. One of these nodules was large enough to 
permit assay of oestrogen receptors, and was found to contain 
twice as many receptor sites as the surrounding normal mam-
mary tissue (204 vs. 98 fmoles/mg protein). Pituitary tumours 
were found only occasionally in irradiated rats~ starting 12 
months after irradiation. 
Mammary gland oestrogen receptors 
Figure shows levels of mammary gland oestrogen receptors 
measured in non-irradiated rats at different intervals after 
oestradiol administration. It appears that oestradiol treat-
ment resulted in a decrease of the estimated content of mam-
mary gland oestrogen receptors, although the difference was 
statistically significant only at 2, 4 and 12 months after 
implantation of the oestradiol pellet. The effect of oestra-
diol on oestrogen receptor levels was more pronounced in 
irradiated animals, as shown in Figure 2. At 2 months after 
irradiation, the mammary gland oestrogen receptor content 
was higher in irradiated rats that received no oestrogen 
than in control rats (P < 0.05). This could be due to the 
presence of the small, receptor-rich nodules mentioned 
before. 
A longitudinal quality control for the receptor assay 
could not be performed, because this assay requires the use 
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Figure I. Levels of mammary gland oestrogen receptors in con-
trol rats (open bars) and in oestrogen-treated rats 
(shaded bars), measured at different intervals after the 
start of the oestradiol treatment. Results are means + s.e.m., 
n = 4-8. !tp < 0.05 vs. control rats (Wilcoxon's test)-:-
of fresh tissue, which cannot be stored as a homogenous pool. 
Nevertheless, to exclude the possibility that the observed 
differences in receptor levels reflected experimental errors 
due to a possible incomplete exchange during the assay, in 
each receptor assay series oestrogen receptors were also 
estimated in the uterus of one of the animals used. The 
oestrogen receptor content of uterine tissue from oestrogen-
treated animals was 257 ~ 22 fmoles/mg protein (mean~ s.e.m., 
n = 31), as compared to 263 ~ 26 fmoles/mg protein (mean+ 
s.e.m., n 21) in tissue from animals which received no 
oestrogen pellet. From these results we have concluded, that 
the decrease in oestrogen receptor content observed in the 
mammary glands of oestrogen-treated animals is not caused by 
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Figure 2. Levels of mammary gland oestrogen receptors in irra-
diated rats (open bars) and in irradiated rats 
treated with oestradiol (shaded bars), at different intervals 
after the start of the oestradiol treatment. Results are means 
+ s.e.m., n = 4-8. !l:.p < 0.05 vs. irradiated rats (Wilcoxon's 
"test). 
incomplete exchange of oestradiol from its receptor. 
Plasma prolactin 
Plasma prolactin levels, measured at different time intervals 
after oestrogen treatment, are shown in Figure 3 for non-
irradiated rats and in Figure 4 for irradiated rats. Oestra-
diol implantation caused a marked increase·in prolactin 
levels. Radiation had no effect on plasma prolactin in 
oestrogen-treated rats, nor in rats which were not given an 
oestrogen pellet. From Figure 3 it is apparent, that the 
plasma prolactin concentration in control rats increases 
with ageing. 
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Figure 3. Plasma prolactin concentrations in control rats 
(open bars) and in oestradiol-treated rats (shaded 
bars) at different time intervals after the start of oestra-
diol treatment. Results are means + s.e.m., n = 3-8. 
~p < 0.05 (Wilcoxon's test). 
Plasma oestradiol 
Plasma oestradiol concentrations were estimated to evaluate 
the release of oestradiol from the oestradiol pellet. The 
results given in Table 2 show, that oestrogen treatment 
caused no significant increase in the plasma oestradiol con-
centration, as compared to the levels estimated in the met-
oestrus phase of the cycle in animals which were not treated 
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Figure 4. Plasma prolactin concentrations in irradiated rats 
(open bars) and in irradiated rats treated with 
oestradiol (shaded bars) at different time intervals after 
the start of the oestradiol treatment. Results are means + 
s.e.m., n = 3-8. ~p < 0.05 (Wilcoxon's test). 
with oestradiol. Yet the oestradiol treatment was sufficient 
to stop the oestrus cycle, to retard the growth and to stimu-
late prolactin secretion. Plasma oestradiol was elevated in 
irradiated rats from 4 to 8 months after irradiation. Such an 
effect was not observed for oestrogen-treated irradiated 
animals. 
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Table 2. Plasma oestradiol concentration in untreated rats, 
oestrogen-treated rats, irradiated rats and oestrogen-
treated irradiated rats at different time intervals after the 
start of the treatment. Results are means + s.e.m. (n) or indi-
vidual values (n = l or 2). In cyclic rats,-plasma samples were 
taken in the morning of the day of metoestrus. 
Plasma oestradiol (pg/ml) 
Time after 
treatment untreated oestrogen radiation oestrogen 
(months) + 
radiation 
2 46+ 9 (6) 101-137 ( 2) 46+10 (5) 50+25 ( 3) 
4 79+ 9 (6) 233+66 (4)"" 67+ 8 (6)" 
6 49+ 6 ( 3) 9 6+ 20 (4) 88+ 7 (3)" 95+15 ( 6) 
8 54+ 7 ( 5) 92+ 33 (3) 82+ 8 (4)" 60+ 9 (4) 
I 0 54 ( I ) 77+ I I ( 3) 52+ 6 ( 4) 61+ 7 (6) 
I 2 69+17 (4) 61+ 23 ( 3) 33+ 5 (5) 52+ 6 ( 5) 
14 48+ 9 (4) 67+ 25 ( 6) 38+12 ( 5) 141+26 (6)" 
" p < 0. OS vs. corresponding control (Student's t-test) 
up 
< 0.05 vs. preceding value 
DISCUSSION 
The results of the present study demonstrate that subcutaneous 
oestradiol implantation causes a decrease of the content of 
oestrogen receptors in mammary glands of irradiated rats as 
well as in rats which were not irradiated (Figures 1 & 2). 
Radiation had no additional effect on oestrogen receptor 
levels, although the combined effects of the dosages of 
oestradiol and radiation used in this study are known to act 
synergistically in the development of malignant mammary 
tumours (Van Bekkum et al., 1979). The decrease in mammary 
tissue oestrogen receptor content theoretically could reflect 
occupancy of receptors by the oestradiol administered and in-
complete exchange with the radioactive ligand. However, the 
results of estimations of oestrogen receptors in uterine 
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tissue obtained from the same oestradiol-treated rats did not 
show a decrease. From this observation we have concluded~ 
that the decrease of the oestrogen receptor content of mam-
mary tissue is not caused by incomplete exchange. 
The data presented in Figures 3 & 4 clearly demonstrate~ that 
implantation of an oestradiol-containing pellet early in life 
results in a prolonged increase in the concentration of pro-
lactin in the plasma. In the present study~ no attempt was 
made to demonstrate a possible (co-)carcinogenic action of 
prolactin on the mammary gland~ but this has been suggested 
in the literature (e.g. Meites~ 1972; Welsh & Nagasawa~ 
1977). The large increase in pituitary prolactin release ob-
served in the present study is in contrast to observations 
reported by Stone~ Holtzman & Shellabarger (1979). These 
authors observed only a small but significant increase in 
plasma prolactin levels in their Sprague-Dawley rats and de-
tected no pituitary tumours during an observation period of 
7 months. ACI rats, however, responded to diethylstilboestrol 
treatment with an increase in the plasma prolactin concentra-
tion comparable to the increase observed after oestradiol 
implantation in the Sprague-Dawley rats used in the present 
study. It appears from this observation, that large differ-
ences exist between the different substrains of Sprague-
Dawley rats. 
In untreated rats of the Sprague-Dawley substrain used in the 
present study, the incidence of malignant mammary tumours was 
7%. In rats treated with oestradiol and in rats irradiated 
with 2 Gy of X-rays the observed incidences of malignant mam-
mary tumours were 5% and 0% respectively, whereas in oestra-
diol-treated irradiated rats an incidence of 25% was observed 
(Van Bekkum et al., 1979). This synergistic effect of radia-
tion and oestrogens in the occurrence of malignant mammary 
tumours was not accompanied by an increased oestrogen receptor 
content of the mammary tissue. Therefore, we have concluded 
that it is unlikely that the co-carcinogenic effect of oestro-
gens in rat mammary carcinogenesis is mediated through an in-
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crease in the number of oestrogen receptors in the mammary 
tissue, as might have been expected from the observations of 
Sarff & Gorski (1971) and Mester & Baulieu (1975). These 
authors reported, based on short-term experiments with uterine 
tissue, that oestrogens can induce the synthesis of their own 
receptors. It appears from the results of the present study, 
that this does not apply for mammary tissue during long-term 
experiments. 
From the present results, it would appear that the effect of 
oestrogens on mammary tumour development in the rat could be 
related to a decrease in the oestrogen receptor content of 
the mammary tissue, to increased prolactin secretion, or to 
the disappearance of cyclic fluctuations in the plasma oestra-
diol concentration. However, all these changes are present 
well before the manifestation of mammary tumours (Broerse et 
al., 1978) and further investigations will have to determine 
whether and which, if any, of these effects is involved in 
the action of oestrogens on rat mammary carcinogenesis. 
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